


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:47:57Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405452" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405452</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>npjbiofilms</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Biofilms Microbiomes</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Biofilms Microbiomes</journal-id><journal-id journal-id-type="pmc-domain-id">3133</journal-id><journal-id journal-id-type="pmc-domain">npjbiofilms</journal-id><journal-title-group><journal-title>NPJ Biofilms and Microbiomes</journal-title></journal-title-group><issn pub-type="epub">2055-5008</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405452</article-id><article-id pub-id-type="pmcid-ver">PMC12405452.1</article-id><article-id pub-id-type="pmcaid">12405452</article-id><article-id pub-id-type="pmcaiid">12405452</article-id><article-id pub-id-type="pmid">40897718</article-id><article-id pub-id-type="doi">10.1038/s41522-025-00819-2</article-id><article-id pub-id-type="publisher-id">819</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Huang</surname><given-names initials="L">Lihaoyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="C">Chunyan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Jiang</surname><given-names initials="A">Aimin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="L">Lingxuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mou</surname><given-names initials="W">Weiming</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="K">Kailai</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cui</surname><given-names initials="C">Cui</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cui</surname><given-names initials="X">Xinfang</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lin</surname><given-names initials="A">Anqi</given-names></name><address><email>smulinanqi0206@i.smu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Luo</surname><given-names initials="P">Peng</given-names></name><address><email>luopeng@smu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wei</surname><given-names initials="T">Ting</given-names></name><address><email>weitingyouyou@qq.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01vjw4z39</institution-id><institution-id institution-id-type="GRID">grid.284723.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8877 7471</institution-id><institution>Department of Oncology, Zhujiang Hospital, </institution><institution>Southern Medical University; Donghai County People&#8217;s Hospital (Affiliated Kangda College of Nanjing Medical University), </institution></institution-wrap>Lianyungang, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01vjw4z39</institution-id><institution-id institution-id-type="GRID">grid.284723.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8877 7471</institution-id><institution>Department of Oncology, Zhujiang Hospital, </institution><institution>Southern Medical University, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bjs0p66</institution-id><institution-id institution-id-type="GRID">grid.411525.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 1599</institution-id><institution>Department of Urology, Changhai hospital, </institution><institution>Naval Medical University (Second Military Medical University), </institution></institution-wrap>Shanghai, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0220qvk04</institution-id><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution>Department of Urology, Shanghai General Hospital, </institution><institution>Shanghai Jiao Tong University School of Medicine, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0400g8r85</institution-id><institution-id institution-id-type="GRID">grid.488530.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 6191</institution-id><institution>Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, </institution><institution>Collaborative Innovation Center for Cancer Medicine, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>Department of Microbiology, State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong, China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">478289</issue-id><elocation-id>180</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41522_2025_Article_819.pdf"/><abstract id="Abs1"><p id="Par1">Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, with the microbiome significantly influencing treatment outcomes. Analysis of 4663 studies (2014.01-2024.10) identified 71 eligible randomized controlled trials (RCTs) and cohort studies (41 viral, 30 bacterial). Analyses included subgroup assessments by cancer type, microbial taxa, and ICI regimens. Among 4663 identified studies, 71 met inclusion criteria (41 viral, 30 bacterial). Viral status, particularly hepatitis B virus (HBV) and human papillomavirus (HPV), significantly associated with ORR and DCR. Bacterial enrichment correlated with improved survival in hepatobiliary (OS: HR&#8201;=&#8201;4.33, 95%CI: 2.20&#8211;8.50) and lung cancers (PFS: HR&#8201;=&#8201;1.70, 95%CI: 1.04&#8211;2.78). Multi-microbiome models demonstrated superior outcome prediction, with microbial diversity correlating with improved PFS (HR&#8201;=&#8201;0.64, 95%CI: 0.42&#8211;0.98). Viral status showed cancer-specific associations with SAEs. The microbiome serves as a valuable predictor of ICI outcomes. Future studies should emphasize large-scale RCTs, standardized assessment methods, and host-microbiome interactions.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Clinical microbiology</kwd><kwd>Pathogens</kwd><kwd>Clinical microbiology</kwd><kwd>Microbiome</kwd></kwd-group><funding-group><award-group><funding-source><institution>Guangdong Provincial Medical Science and Technology Research</institution></funding-source><award-id>B2023341</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82172750</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Over the past decade, the emergence and widespread application of immune checkpoint inhibitors (ICIs) have not only illuminated the promising integration of precision oncology with immunology but also marked a transformative milestone in cancer immunotherapy. Targeted immunotherapeutic agents, such as inhibitors of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4), enhance the immune system&#8217;s ability to recognize and eliminate tumors by blocking immune checkpoint protein-mediated immune evasion mechanisms in cancer cells. These therapies have significantly improved clinical outcomes and prognoses for patients with various advanced or recurrent cancers<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. However, response rates vary substantially between patients, with many showing limited or no benefit. This heterogeneity in treatment response creates an urgent need for reliable predictive biomarkers to guide patient selection and optimize therapeutic strategies<sup><xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">Several biomarkers, including PD-L1 expression, tumor mutational burden, DNA mismatch repair deficiency, immune cell and cytokine infiltration, and metabolic tumor volume via [18&#8201;F]FDG-PET/CT, have shown clinical value in predicting ICI efficacy<sup><xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref></sup>. However, their application is limited by factors such as genomic-immune interactions, tumor heterogeneity, assay variability, spatiotemporal sampling differences, and the absence of standardized scoring systems tailored to specific drugs or tumor types<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. While combination ICI therapies have shown significant benefits in advanced cancers<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, research on biomarkers for these strategies remains insufficient<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. These challenges hinder precise patient selection and treatment decisions. Addressing these limitations is critical for advancing the precision of immunotherapy. Consequently, the development and refinement of novel biomarkers have become pivotal not only for improving the efficacy of precision immunotherapy but also for laying a foundation for the exploration of innovative immunotherapeutic strategies.</p><p id="Par4">Advances in symbiotic microbiome genomics and spatial transcriptomics have increasingly clarified the intricate relationship between tumor immunotherapy and the microbiome, opening new avenues for biomarker development. Evidence suggests that variations in microbiome composition, diversity, and metabolic products profoundly regulate immune cell responses and infiltration, thereby influencing ICI efficacy<sup><xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref></sup>. Preclinical studies have shown that specific gut microbiota, such as <italic toggle="yes">Bacteroides fragilis</italic> and <italic toggle="yes">Bifidobacterium</italic>, enhance CD8&#8201;+&#8201;T cell infiltration and effector functions, improving melanoma responses to ICIs<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. Additionally, ICI responders often exhibit higher gut microbiome diversity, strongly associated with sustained clinical benefit<sup><xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref></sup>. This may involve mechanisms such as microbiota-induced T cell responses, molecular mimicry between microbial and tumor antigens, and microbial metabolite regulation of immune homeostasis<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. However, controversies remain regarding the key microbial species influencing ICI efficacy, the role of microbiome diversity in prognosis, and balancing therapeutic benefits with adverse event risks<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. As a significant oncogenic factor, viral infections have also garnered attention in the context of ICIs. While systemic ICI therapy may lead to viral reactivation<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, studies suggest that certain viral infections not only fail to increase the risk of virus-associated complications but may also enhance ICI efficacy by suppressing viral replication<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. Given inconsistencies in current research, a systematic evaluation of microbiome composition&#8217;s impact on ICI efficacy and safety is critical for advancing precision immunotherapy strategies.</p><p id="Par5">Given the substantial heterogeneity in immunotherapeutic response and the limited predictive accuracy of established biomarkers, we conducted a comprehensive meta-analysis to evaluate the predictive utility of bacterial and viral microbiome components for ICI efficacy and safety across diverse malignancies. The primary objectives are as follows: (1) Evaluate associations between virome and bacteriome composition with objective response rate (ORR) and disease control rate (DCR) in ICIs. (2) Analyze the relationship between different viral infection statuses, tumor types, and ICI regimens on therapeutic response. (3) Evaluate the predictive value of viral infection status for the risk of ICI-associated adverse events. (4) Investigate correlations between bacterial composition and progression-free survival (PFS)/overall survival (OS) in ICI treatments. (5) Examine the influence of microbial diversity on patient prognosis (PFS and OS). Through this comprehensive analysis, we aims to generate evidence-based insights regarding microbiome-derived biomarkers for immunotherapeutic efficacy and toxicity prediction. Ultimately, this work seeks to advance precision immunotherapy by identifying microbiome-based predictive signatures that may inform patient selection for immunotherapy, enhance outcome prediction accuracy, and potentially guide therapeutic microbiome modulation strategies to optimize clinical benefit.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Study characteristics</title><p id="Par6">A total of 4663 articles were identified through the initial database search. After screening titles and abstracts, irrelevant studies were excluded, leaving 979 articles for full-text evaluation. Of these, 393 articles were deemed potentially valuable for data extraction. During this process, studies were excluded for the following reasons: reporting only multivariable-adjusted HRs (<italic toggle="yes">N</italic>&#8201;=&#8201;22), lacking usable efficacy or safety data (<italic toggle="yes">N</italic>&#8201;=&#8201;268), duplicates (<italic toggle="yes">N</italic>&#8201;=&#8201;31), and retractions (<italic toggle="yes">N</italic>&#8201;=&#8201;1). Ultimately, 71 studies were included in the final analysis (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Among the studies evaluating viruses as predictors of ICI outcomes (<italic toggle="yes">N</italic>&#8201;=&#8201;41)<sup><xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR71">71</xref></sup>, 29 studies (39 cohorts) reported ORR, with RRs analyzed in 29 cohorts for ORR and 7 cohorts for DCR. Three studies (5 cohorts) assessed ICI safety in relation to viral predictors. For studies evaluating bacterial predictors (<italic toggle="yes">N</italic>&#8201;=&#8201;30)<sup><xref ref-type="bibr" rid="CR72">72</xref>&#8211;<xref ref-type="bibr" rid="CR101">101</xref></sup>, 19 studies provided HRs for PFS and OS. Basic characteristics of viral- and bacterial-related studies are summarized in Tables <xref rid="MOESM1" ref-type="media">S1</xref> and <xref rid="MOESM1" ref-type="media">S2</xref>, respectively.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Workflow of identification of studies through databases following PRISMA guidelines.</p></caption><graphic id="d33e422" position="float" orientation="portrait" xlink:href="41522_2025_819_Fig1_HTML.jpg"/></fig></p><p id="Par7">The included studies were published between 2014 and 2024, comprising 63 cohort studies (33 viral-related, 30 bacterial-related) and 8 randomized controlled trials (RCTs) evaluating viral predictors. RCT quality was assessed using the Cochrane ROB tool (Table <xref rid="MOESM1" ref-type="media">S3</xref>). Most RCTs were open-label designs without blinding but showed low risk of bias for randomization, missing data, and outcome reporting. Cohort study quality was assessed using the NOS (Table <xref rid="MOESM1" ref-type="media">S4</xref>). Among the 63 cohort studies, 37 cohorts as high-quality studies, NOS scores: &#8805;9 (<italic toggle="yes">N</italic>&#8201;=&#8201;1), &#8805;8 (<italic toggle="yes">N</italic>&#8201;=&#8201;12), &#8805;7 (<italic toggle="yes">N</italic>&#8201;=&#8201;24). 26 cohorts as moderate-quality studies, NOS scores: &#8805;6 (<italic toggle="yes">N</italic>&#8201;=&#8201;17), &#8805;5 (<italic toggle="yes">N</italic>&#8201;=&#8201;8), &gt;4 (<italic toggle="yes">N</italic>&#8201;=&#8201;1). All included studies met at least moderate-quality standards. Funnel plot analysis showed that ORR-related cohorts (<italic toggle="yes">N</italic>&#8201;=&#8201;29) exhibited slight left-sided asymmetry (Fig. <xref rid="MOESM1" ref-type="media">S1A</xref>), but this funnel plot asymmetry did not reach statistical significance (Egger&#8217;s test: <italic toggle="yes">t</italic>&#8201;=&#8201;&#8722;0.97, <italic toggle="yes">P</italic>&#8201;=&#8201;0.34). Meanwhile, substantial heterogeneity existed between studies (&#964;&#178;&#8201;=&#8201;2.8799), suggesting that this asymmetry likely stemmed from true differences between studies rather than publication bias. The funnel plot for OS-related cohorts (<italic toggle="yes">N</italic>&#8201;=&#8201;23) displayed mild right-sided asymmetry (Fig. <xref rid="MOESM1" ref-type="media">S1B</xref>), indicating potential bias or small sample effects. However, the overall Egger&#8217;s test results suggested this asymmetry was not statistically significant (<italic toggle="yes">t</italic>&#8201;=&#8201;0.67, <italic toggle="yes">P</italic>&#8201;=&#8201;0.51), accompanied by considerable between-study heterogeneity (&#964;&#178;&#8201;=&#8201;6.5355). PFS-related cohorts (<italic toggle="yes">N</italic>&#8201;=&#8201;22) demonstrated good symmetry, with Egger&#8217;s test also indicating that funnel plot asymmetry was not pronounced (<italic toggle="yes">t</italic>&#8201;=&#8201;0.31), and publication bias was not significant (<italic toggle="yes">P</italic>&#8201;=&#8201;0.76) (Fig. <xref rid="MOESM1" ref-type="media">S1C</xref>).</p></sec><sec id="Sec4"><title>Microbiota and ICIs efficacy with ORR</title><p id="Par8">Due to variations in endpoints and reported outcomes in studies evaluating the predictive value of viruses and bacteria in ICI efficacy, 34 cohorts reported ORR for microbial exposure vs. control groups, while only 25 and 22 cohorts provided HRs for PFS and OS, respectively. Given these discrepancies, ORR was selected as the primary metric for assessing the predictive value of baseline microbiota on ICI outcomes, including viruses, individual bacterial species, and bacterial communities. The meta-analysis revealed a pooled RR of 1.29 (95% CI: 1.07&#8211;1.55, <italic toggle="yes">P</italic>&#8201;=&#8201;0.049) across 34 cohorts, with moderate heterogeneity (I<sup>2</sup>&#8201;=&#8201;55.6%), indicating a significant association between baseline microbiota and ICI efficacy. Subgroup analysis showed a pooled RR of 1.28 (95% CI: 1.11&#8211;1.47, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) for virus-related cohorts (<italic toggle="yes">N</italic>&#8201;=&#8201;27), with lower heterogeneity (I<sup>2</sup>&#8201;=&#8201;47.9%), suggesting that baseline viral status is a critical predictor of ICI response. In contrast, the predictive value of bacterial communities was relatively limited, with the small number of bacterial-related cohorts (<italic toggle="yes">N</italic>&#8201;=&#8201;5) reporting ORR underscoring the need for further evidence to confirm this conclusion (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>). Additionally, meta-analysis encompassing 21 monotherapeutic ICI (Anti-PD-1/PD-L1/CTLA-4) cohorts demonstrated a combined RR of 1.40 (95% CI: 1.23&#8211;1.60, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;21), with a heterogeneity index I&#178;of 25.9%. This finding suggests that microbial status may serve as a valuable predictive biomarker for response to single-agent ICI therapy. Notably, this investigation extended to unconventional immune checkpoint blockers (ICBs), including KL-A167 (Shi et al.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>) and Bintrafusp alfa (Chiang et al.<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>). Interestingly, microbial status exhibited a negative correlation with efficacy for these novel ICBs, yielding a RR of 0.58 (95% CI: 0.41&#8211;0.82, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002, <italic toggle="yes">N</italic>&#8201;=&#8201;4). Nevertheless, given that the analysis incorporated only two specific unconventional ICBs, the relationship between microbial status and clinical outcomes for these emerging therapeutic agents warrants further validation through more comprehensive and diverse clinical investigations (Fig. <xref rid="MOESM1" ref-type="media">S1D</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Microbial predictors of immunotherapy efficacy based on objective response rate (ORR) and risk ratio (RR).</title><p><bold>A</bold> Association of microbiota with immunotherapy efficacy. <bold>B</bold> Association of viruses with immunotherapy efficacy across different virus types, tumor types, and immunotherapy strategies.</p></caption><graphic id="d33e549" position="float" orientation="portrait" xlink:href="41522_2025_819_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Virus-associated efficacy analysis with ORR</title><p id="Par9">Using ORR as the primary endpoint (<italic toggle="yes">N</italic>&#8201;=&#8201;29), subgroup analysis was conducted to compare viral-positive versus viral-negative groups, as well as elevated versus reduced EBV DNA levels, as observation and control groups, respectively (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). The viral subgroup analysis revealed a pooled RR of 1.36 (95% CI: 1.09&#8211;1.69, <italic toggle="yes">P</italic>&#8201;=&#8201;0.008) with moderate heterogeneity (I<sup>2</sup>&#8201;=&#8201;51.1%), confirming a significant association between viral status and treatment efficacy. Further analysis by viral type identified hepatitis B virus (HBV) and human papillomavirus (HPV) as strong predictors of ICI outcomes, with RRs of 1.36 (95% CI: 1.10&#8211;1.67, <italic toggle="yes">P</italic>&#8201;=&#8201;0.005, <italic toggle="yes">N</italic>&#8201;=&#8201;9) and 1.61 (95% CI: 1.19&#8211;2.18, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002, <italic toggle="yes">N</italic>&#8201;=&#8201;7), respectively. Notably, heterogeneity was low in these subgroups (HBV: I<sup>2</sup>&#8201;=&#8201;16.7%; HPV: I<sup>2</sup>&#8201;=&#8201;0.0%). Subgroup analysis by tumor type revealed differences in the predictive performance of viral status across cancers (RR: 1.36 [95% CI: 1.10&#8211;1.67], <italic toggle="yes">P</italic>&#8201;=&#8201;0.588), likely reflecting the distribution of viral types among tumors. HBV and HPV were key contributors to the overall results. Viral status was notably correlated with ICI efficacy in hepatobiliary cancers, with a pooled RR of 1.71 (95% CI: 1.22&#8211;2.38, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002, I<sup>2</sup>&#8201;=&#8201;0.0%), consistent with findings from the HBV subgroup, underscoring HBV as a critical predictive factor for ICI response. Analysis of ICI regimens also highlighted virus as significant predictors of treatment efficacy (<italic toggle="yes">P</italic>&#8201;=&#8201;0.034). In the ICI monotherapy subgroup, the pooled RR was 1.46 (95%CI: 1.22&#8211;1.74, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;16), indicating a robust correlation between viral status and treatment outcomes in single-agent ICI. However, viral status did not reach statistical significance as a predictor in combination therapies or specialized ICB regimens. In the subgroup analysis based on sampling sites, tissue-derived samples exhibited a pooled RR of 1.76 (95% CI: 1.33&#8211;2.33, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;8), indicating that, compared to plasma-based assessments, tumor tissue-derived viral signatures may serve as a more reliable predictor of ORR (Fig. <xref rid="MOESM1" ref-type="media">S6A</xref>). Supplementary results are provided in Fig. <xref rid="MOESM1" ref-type="media">S2</xref>&#8211;<xref rid="MOESM1" ref-type="media">S4</xref> (ORR and 95% CI for virus-positive patients stratified by viral group, tumor type, and ICB regimens) and Fig. <xref rid="MOESM1" ref-type="media">S6B</xref> (impact of viral status on PFS with HRs). The pooled ORR was 27% (95% CI: 25&#8211;29%), demonstrating statistical significance across viral and tumor subgroups with moderate heterogeneity (I<sup>2</sup>&#8201;=&#8201;63.6%). These findings underscore the critical role of baseline viral status, particularly for specific viral types and cancer contexts, in predicting ICI efficacy.</p></sec><sec id="Sec6"><title>Virus-associated efficacy analysis with DCR</title><p id="Par10">Using DCR as a secondary endpoint (<italic toggle="yes">N</italic>&#8201;=&#8201;7), subgroup analysis was conducted on seven included study cohorts (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The pooled analysis revealed significant heterogeneity (I<sup>2</sup>&#8201;=&#8201;82.7%) and a combined RR of 0.99 (95% CI: 0.71&#8211;1.39, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), indicating substantial variability in the predictive value of viral status for DCR, which may limit its utility as an independent prognostic marker. Analysis by viral type showed contrasting predictive patterns: the pooled RR for HBV was 1.29 (95% CI: 1.10&#8211;1.50, <italic toggle="yes">P</italic>&#8201;=&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;4), demonstrating a significant positive correlation with DCR, whereas the RR for EBV was 0.63 (95% CI: 0.52&#8211;0.77, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3), indicating a significant negative correlation with DCR. Both subgroups exhibited low heterogeneity (HBV: I<sup>2</sup>&#8201;=&#8201;28.1%; EBV: I<sup>2</sup>&#8201;=&#8201;0.0%), suggesting consistent results within these cohorts. Subgroup analysis by tumor type revealed that viral status was a significant predictor of DCR in lung cancer, hepatobiliary cancer, and nasopharyngeal carcinoma (NPC). EBV consistently demonstrated a negative predictive value in NPC (RR&#8201;=&#8201;0.63, 95% CI: 0.52&#8211;0.77, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3). HBV showed strong predictive value for DCR in lung cancer (RR&#8201;=&#8201;1.73, 95% CI: 1.13&#8211;2.65, <italic toggle="yes">P</italic>&#8201;=&#8201;0.012, <italic toggle="yes">N</italic>&#8201;=&#8201;1) and hepatobiliary cancer (RR&#8201;=&#8201;1.69, 95% CI: 1.02&#8211;2.80, <italic toggle="yes">P</italic>&#8201;=&#8201;0.043, <italic toggle="yes">N</italic>&#8201;=&#8201;1). However, these results were drawn from single cohorts for each tumor type, limiting the statistical power and emphasizing the need for further validation. Subgroup analysis of ICB treatment regimens revealed distinct predictive patterns for viral status. The pooled RR of monotherapy group (4 cohorts) was 1.29 (95% CI: 1.10&#8211;1.50, <italic toggle="yes">P</italic>&#8201;=&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;4), consistent with the predictive value observed for HBV. Conversely, the pooled RR for other ICB treatment regimens was 0.63 (95% CI: 0.52&#8211;0.77, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3), aligning with the negative predictive value of EBV. These findings reflect the differing roles of HBV and EBV as predictors in ICB therapies, highlighting their distribution patterns across treatment regimens and tumor types.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Virus-associated prediction of immunotherapy efficacy measured by disease control rate (DCR) and risk ratio (RR), across different virus types, tumor types, and immunotherapy strategies.</p></caption><graphic id="d33e691" position="float" orientation="portrait" xlink:href="41522_2025_819_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec7"><title>Bacteria-associated prognostic analysis with HR</title><p id="Par11">This study evaluated the impact of bacterial status on ICI efficacy using HRs for PFS and OS. A total of 19 studies were included in the subgroup analysis (PFS: 14 studies; OS: 12 studies), comparing bacteria-presence vs. bacteria-absence groups and enriched vs. depleted bacterial communities. Subgroup analysis by tumor type revealed no statistically significant overall predictive effect of bacterial status on OS or PFS. However, the predictive value of bacteria varied across specific tumor types. For OS, bacterial status showed statistical significance in melanoma and mesothelioma, but these findings were based on single study cohorts, limiting their reliability. In contrast, bacterial enrichment in hepatobiliary cancers demonstrated a strong predictive value for OS compared to bacterial depletion (HR&#8201;=&#8201;4.33 [95% CI: 2.20&#8211;8.50], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3), with no observed heterogeneity (I<sup>2</sup>&#8201;=&#8201;0.0%) (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>). For PFS, bacterial status displayed significant prognostic value in several tumor types. In gastrointestinal cancers, bacterial status was negatively associated with PFS (HR&#8201;=&#8201;0.82 [95% CI: 0.70&#8211;0.96], P&#8201;=&#8201;0.016, <italic toggle="yes">N</italic>&#8201;=&#8201;4), suggesting a potential reduction in sustained ICI benefits. Conversely, in lung cancer, bacterial status was positively correlated with PFS (HR&#8201;=&#8201;1.70 [95% CI: 1.04&#8211;2.78], <italic toggle="yes">P</italic>&#8201;=&#8201;0.035, <italic toggle="yes">N</italic>&#8201;=&#8201;2). Similarly, in hepatobiliary cancers, enriched bacterial communities were linked to significantly improved PFS compared to depleted communities (HR&#8201;=&#8201;2.33 [95% CI: 1.54&#8211;3.53], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3), consistent with the OS analysis. In contrast, under a fixed-effect model, enrichment of bacteria showed a potential negative correlation with PFS in lung cancer (HR&#8201;=&#8201;0.75 [95% CI: 0.58&#8211;0.96], <italic toggle="yes">P</italic>&#8201;=&#8201;0.023, <italic toggle="yes">N</italic>&#8201;=&#8201;5). In mesothelioma and urothelial carcinoma, single studies suggested specific bacterial enrichments were associated with PFS (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>), but further research is needed to confirm the generalizability of bacteria as predictive markers.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Bacterial predictors of immunotherapy outcomes across various tumor types.</title><p><bold>A</bold> Overall survival(OS); <bold>B</bold> Progression free survival(PFS).</p></caption><graphic id="d33e746" position="float" orientation="portrait" xlink:href="41522_2025_819_Fig4_HTML.jpg"/></fig></p><p id="Par12">At the bacterial phylum level (Fig. <xref rid="Fig5" ref-type="fig">5A, B</xref>), all included studies focused on single bacterial taxa. Results showed that <italic toggle="yes">Verucomicrobia</italic> enrichment was significantly associated with OS in one study (HR&#8201;=&#8201;2.63 [95% CI: 1.53&#8211;4.52], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;1), while <italic toggle="yes">Bacteroidetes</italic> enrichment was significantly associated with PFS in another study (HR&#8201;=&#8201;2.54 [95% CI: 1.18&#8211;5.44], <italic toggle="yes">P</italic>&#8201;=&#8201;0.017, <italic toggle="yes">N</italic>&#8201;=&#8201;1). However, as these findings stem from single study cohorts, the predictive value of bacterial phyla for ICI outcomes remains inconclusive and requires further validation. Overall, no significant association was identified between specific bacterial phyla and OS or PFS following ICI treatment. To explore the predictive value of bacteria in greater depth, studies were classified into two subgroups based on bacterial composition: single versus multiple bacterial communities (Fig. <xref rid="Fig5" ref-type="fig">5C, D</xref>). Subgroup analysis of OS showed no significant impact of either single or multiple bacterial communities on OS. However, enrichment of multiple bacterial taxa demonstrated a potential negative association with OS (HR&#8201;=&#8201;0.54 [95% CI: 0.29&#8211;1.0], <italic toggle="yes">P</italic>&#8201;=&#8201;0.049, <italic toggle="yes">N</italic>&#8201;=&#8201;1). Since the upper bound of the CI equals 1.0 and this result is from a single study, further evidence is necessary to confirm its robustness. Similarly, no significant association was observed between single or multiple bacterial communities and PFS. However, under a fixed-effect model, enrichment of multiple bacterial taxa showed a potential negative correlation with PFS (HR&#8201;=&#8201;0.64 [95% CI: 0.42&#8211;0.98], <italic toggle="yes">P</italic>&#8201;=&#8201;0.039, <italic toggle="yes">N</italic>&#8201;=&#8201;2). Notably, studies evaluating the predictive value of multiple bacterial communities were limited in number and sample size, with high heterogeneity (I&#178;&#8201;=&#8201;81.3%), underscoring the need for further research.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Bacteria as predictive factors for immunotherapy outcomes in various bacterial phyla and mono-/poly-bacterial models.</title><p>Association of different bacterial phyla with overall survival (OS) (<bold>A</bold>) and progression free survival (PFS) (<bold>B</bold>). Comparison of mono-bacterial vs. poly-bacterial models for OS (<bold>C</bold>) and PFS (<bold>D</bold>).</p></caption><graphic id="d33e807" position="float" orientation="portrait" xlink:href="41522_2025_819_Fig5_HTML.jpg"/></fig></p><p id="Par13">To further evaluate the impact of high-throughput sequencing heterogeneity on the predictive role of bacterial abundance in ICIs, all studies were standardized to a uniform sample environment, stool. The results indicated that metagenomic sequencing associated microbial composition with worse OS (HR&#8201;=&#8201;3.20 [95% CI: 2.10&#8211;4.88], <italic toggle="yes">P</italic>&#8201;=&#8201;0.000, <italic toggle="yes">N</italic>&#8201;=&#8201;4). In terms of PFS (<italic toggle="yes">N</italic>&#8201;=&#8201;13), no significant differences were observed between the two sequencing methods. Overall, the differences in sequencing techniques did not reach statistical significance, and high heterogeneity was observed among the studies (Fig. <xref rid="MOESM1" ref-type="media">S5A, B</xref>).</p></sec><sec id="Sec8"><title>Safety evaluation</title><p id="Par14">Three studies (<italic toggle="yes">N</italic>&#8201;=&#8201;5) evaluated the association between viral status and ICI-related adverse events (irAEs) as well as sever adverse events (SAEs). These studies compared the incidence of irAEs (all grades) and &#8805;Grade 3 SAEs between virus-positive and virus-negative patients, with a particular focus on HBV and HPV. The overall analysis showed no significant correlation between viral status and irAEs across subgroups (RR&#8201;=&#8201;1.04, 95% CI: 0.92&#8211;1.17, <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05) (Fig. <xref rid="MOESM1" ref-type="media">S6C</xref>). Similarly, the pooled analysis for SAEs revealed no significant association (RR&#8201;=&#8201;1.10, 95% CI: 0.57&#8211;2.25, <italic toggle="yes">P</italic>&#8201;=&#8201;0.570) and high heterogeneity (I&#178;&#8201;=&#8201;72.8%) (Fig. <xref rid="MOESM1" ref-type="media">S6D</xref>). When stratified by tumor type, the analysis of three cohorts focusing on hepatobiliary cancers showed a marginally significant association between viral status and SAEs (RR&#8201;=&#8201;0.62, 95% CI: 0.39&#8211;1.00, <italic toggle="yes">P</italic>&#8201;=&#8201;0.048, <italic toggle="yes">N</italic>&#8201;=&#8201;3). However, given that the upper bound of the CI equals 1.0, this finding requires further validation with larger sample sizes. Analysis of ICI treatment regimens revealed that, in two monotherapy cohorts, viral status was significantly associated with an increased risk of SAEs (RR&#8201;=&#8201;2.31, 95% CI: 1.35&#8211;3.94, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002, N&#8201;=&#8201;2), suggesting that viral infections may heighten the risk of SAEs. Notably, the ICI combination therapy cohorts overlapped with the hepatobiliary cancer studies, and the results were mutually supportive.</p></sec></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p id="Par15">This study systematically evaluated the predictive value of the microbiome for the efficacy and safety of ICIs in cancer treatment. The meta-analysis revealed that the relationship between the microbiome and ICI efficacy varied by microbial type, tumor type, treatment strategy, sampling site, and bacterial model configurations. Overall, baseline microbiomes demonstrated a significant predictive effect on ORR to ICIs (RR&#8201;=&#8201;1.29, 95% CI: 1.07&#8211;1.55, <italic toggle="yes">P</italic>&#8201;=&#8201;0.049, <italic toggle="yes">N</italic>&#8201;=&#8201;34), with viral microbiomes and monotherapeutic ICI showing particularly strong predictive performance. Subgroup analyses further highlighted the role of viruses in predicting ICI efficacy, with a pooled RR of 1.36 (95% CI: 1.09&#8211;1.69, <italic toggle="yes">P</italic>&#8201;=&#8201;0.008, <italic toggle="yes">N</italic>&#8201;=&#8201;29). Among viral types, HBV and HPV exhibited superior predictive capacity. Viral status also correlated significantly with clinical benefits in hepatobiliary cancers (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002, <italic toggle="yes">N</italic>&#8201;=&#8201;10) and in patients receiving monotherapy (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;16). Additionally, tumor tissue sampling appeared to enhance the predictive value of viral biomarkers for ORR(RR&#8201;=&#8201;11.76) (95% CI: 1.33&#8211;2.33, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;8). Supplementary analyses using DCR confirmed the predictive potential of specific viruses, with variability across viral types. HBV was positively associated with ICI efficacy (RR&#8201;=&#8201;1.29, 95% CI: 1.10&#8211;1.50, <italic toggle="yes">P</italic>&#8201;=&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;4), whereas EBV was negatively associated (RR&#8201;=&#8201;0.63, 95% CI: 0.52&#8211;0.77, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3). For bacteria, while the overall predictive effect on ICI outcomes was inconsistent, bacterial enrichment was significantly associated with clinical benefits in specific tumor types, including hepatobiliary cancers (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">N</italic>&#8201;=&#8201;3), gastrointestinal tumors (<italic toggle="yes">P</italic>&#8201;=&#8201;0.016, <italic toggle="yes">N</italic>&#8201;=&#8201;4), and lung cancer (<italic toggle="yes">P</italic>&#8201;=&#8201;0.035, <italic toggle="yes">N</italic>&#8201;=&#8201;2). Moreover, multi-microbiome predictive models demonstrated a significant association with PFS in ICI treatment (HR&#8201;=&#8201;0.64, 95% CI: 0.42&#8211;0.98, <italic toggle="yes">P</italic>&#8201;=&#8201;0.039, <italic toggle="yes">N</italic>&#8201;=&#8201;2). In terms of safety, viral presence was not significantly associated with the overall occurrence of (S)AEs. However, viral status showed potential predictive value for SAEs in patients with hepatobiliary cancers and those receiving monotherapy. Although the number of included studies and sample sizes were limited, this study provides preliminary evidence supporting the microbiome&#8217;s potential as a predictive biomarker for ICI therapy. These findings lay the groundwork for further research exploring the microbiome&#8217;s application in cancer immunotherapy, highlighting its value as an emerging area of study.</p><p id="Par16">This meta-analysis demonstrates that viruses within the microbiome hold significant predictive value for the clinical efficacy of ICIs, with HBV and HPV showing particularly strong associations with treatment benefits. Notably, viral status exhibited robust predictive performance in ICI therapy for hepatobiliary cancers, validating prior studies suggesting that HBV-associated hepatocellular carcinoma (HCC) patients are likely to benefit from ICIs therapy<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Additionally, no significant alterations in viral load were detected in patients receiving consistent antiviral therapy during ICI treatment, with no documented HBV reactivation or HCV recurrence observed<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. These findings support the hypothesis that specific viruses can enhance antitumor immune responses<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. Virus-associated tumor microenvironment (TME) may be related to the dynamic transformation and activity of immune cells<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. At the single-cell level, studies have shown that in HBV-associated TME, effector CD8&#8201;+&#8201;T cells undergo function evolution, correlating with improved survival in advanced HCC. Enrichment and activation of HBV-specific tissue-resident memory CD8&#8201;+&#8201;T cells have also been identified as critical mechanisms for effective immunotherapy in HCC<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. Similarly, HBV-specific CD8&#8201;+&#8201;T cells belong to the CD8+ effector/effector memory T cell (CD8+Teff/Tem) subset, exhibiting characteristics similar to circulating effector memory T cells (cTem) and progenitor exhaustion T cells (Tpex). Compared to HBV-T cells, HBV&#8201;+&#8201;T cells demonstrate greater potential for migration, infiltration, memory response, and clonal expansion, supporting enhanced immunotherapeutic responses<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>. Immune-related gene expression profiling in HPV-positive oropharyngeal squamous cell carcinoma has revealed CD8&#8201;+&#8201;T cell enrichment and high checkpoint protein expression in the TME, suggesting that ICIs may activate potent antitumor immunity in these patients<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>. HNSCC is differentiated into immune-hot and immune-cold types based on HPV infection status, with immune-hot HPV&#8201;+&#8201;HNSCC containing various fibroblasts with distinct immunomodulatory functions, particularly IL11+ inflammatory cancer-associated fibroblasts (iCAFs) associated with inflammatory stimuli and CCL19+ fibroblastic reticular cell-like (FRC) cells related to the activation of CD4&#8201;+&#8201;T cells and B cells through lymphotoxin signaling, both of which researchers consider to be associated with positive immunotherapeutic responses<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>. However, there are discrepancies in the predictive role of viral status. Ho et al. compared the clinical benefits of PD-1/PD-L1 inhibitors in HCC patients with and without HBV/HCV infections, finding no significant differences in TME immune cell infiltration subtypes or immune checkpoint molecule expression levels<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>. This discrepancy may be related to the balance of inflammation and immune recognition mechanisms within the TME<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup>. On one hand, viral infections can activate cytokine networks, promoting antitumor immunity by enhancing immune cell activation. On the other hand, chronic viral infections, as oncogenic factors, may impair T cell-specific recognition of virus-infected or tumor-associated cells. Continuous viral replication and chronic inflammatory responses may disrupt immune homeostasis, leading to immune evasion and tissue damage. Our analysis of DCR revealed opposing trends for HBV and EBV. HBV was positively associated with ICI efficacy, while EBV infection correlated with poorer outcomes. Furthermore, patients demonstrating response to anti-PD-1 therapy exhibited significantly enhanced clinical benefits compared to those characterized by Epstein-Barr virus progression (defined as viral DNA load exceeding 1.5-fold baseline), viral response (defined as DNA load below 0.5-fold baseline), or early clearance of plasma EBV DNA<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. These findings align with prior studies indicating that EBV reduces ICI effectiveness through mechanisms such as increasing PD-L1 expression, linking to CD8&#8201;+&#8201;T cell exhaustion, and recruiting immunosuppressive factors<sup><xref ref-type="bibr" rid="CR110">110</xref>&#8211;<xref ref-type="bibr" rid="CR113">113</xref></sup>. Interestingly, McMiller et al. found that EBV-negative gastric cancer exhibited activation of the COX-2/PGE2 pro-inflammatory pathway, significantly suppressing responses to anti-PD-1/PD-L1 therapy<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>. This highlights the complex role of EBV infection in modulating ICI efficacy. While viral status has been proposed as a potential biomarker for ICI efficacy, the variability in findings and mechanistic explanations suggests that its predictive role requires further clarification. Future studies should incorporate larger real-world datasets and well-designed clinical trials to comprehensively explore the predictive value of viral status in ICI therapy.</p><p id="Par17">Notably, numerous investigations have demonstrated a bidirectional immunoregulatory relationship between ICI efficacy and specific bacterial taxa abundance profiles. In melanoma patients responding to immunotherapy, significantly elevated abundances of <italic toggle="yes">Ruminococcaceae</italic> and <italic toggle="yes">Faecalibacterium</italic> have been documented compared to non-responders. Conversely, in microsatellite instability-high CRC patients, <italic toggle="yes">Fusobacterium nucleatum</italic> abundance demonstrated inverse correlation with tumor-infiltrating lymphocyte immunological status<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>. In preclinical murine models, antibiotic-treated mice demonstrated restoration of anti-CTLA-4 immunotherapeutic responses following selective recolonization with <italic toggle="yes">Bacteroides fragilis</italic>, with efficacy correlating with bacterial abundance. This phenomenon appears mediated through <italic toggle="yes">Bacteroides fragilis</italic>-induced enhancement of CD4&#8201;+&#8201;Th1 immune responses within tumor-draining lymph nodes and potentiation of dendritic cell antigen presentation capacity<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Furthermore, anti-CTLA-4 therapy administration did not significantly alter <italic toggle="yes">Bacteroides fragilis</italic> abundance, highlighting the stability of microbiome-immunotherapy interactions in this context. Subsequent investigations have established that <italic toggle="yes">Faecalibacterium spp</italic>. exert immunomodulatory effects in murine models receiving anti-CTLA-4 therapy, whereas <italic toggle="yes">Dorea formicogenerans</italic> specifically enhances anti-PD-L1 therapeutic efficacy<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. In human clinical investigations, Chaput et al. demonstrated significant associations between baseline intestinal microbiota composition and therapeutic response in metastatic melanoma patients receiving ipilimumab treatment. Specifically, patients with <italic toggle="yes">Faecalibacterium</italic>-enriched microbiota exhibited enhanced cellular immunity following ipilimumab administration, characterized by elevated expression of co-stimulatory molecules on CD4&#8201;+&#8201;T cells<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>. However, this investigation lacked prospective longitudinal assessment of microbiome compositional dynamics during ICI therapy, precluding establishment of causal relationships between microbiota alterations and therapeutic outcomes. Given that microbial analyses in existing studies predominantly involve monotherapeutic immunotherapy regimens, or utilized a mixed ICI system to systematically explore the correlation between microbiota and immunotherapy efficacy, current literature lacks robust subgroup analyses examining associations between specific bacterial taxa and distinct immunotherapeutic agents or combination strategies.</p><p id="Par18">Subgroup analysis of sampling sites revealed differences in the correlation between viral status and ICI efficacy across different sampling sites. Notably, viral detection results from tumor tissues may provide more reliable predictions of ICI treatment outcomes. Intratumoral microbes potentially serve as tumor subtype markers, with viruses specifically distributed within tumor tissues triggering or directly participating in specific immune responses, thus more accurately reflecting the actual tumor immune-related conditions. Multiple studies have successively demonstrated that intratumoral microbiota produce multiple effects including metabolic remodeling and immune regulation, thereby influencing tumor immunotherapy responses<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR115">115</xref>&#8211;<xref ref-type="bibr" rid="CR118">118</xref></sup>. Similarly, immune responses within EBV gastric cancer subtypes are associated with EBV-related CD8&#8201;+&#8201;T cells, regulatory T cells(Treg), NK cells, and macrophage infiltration, accompanied by abundant PD-L1 expression. However, current research findings on the correlation between PD-L1 expression levels and patient survival remain highly controversial, indicating significant heterogeneity in EBV gastric cancer subtype responses to anti-PD-1/PD-L1 immunotherapy<sup><xref ref-type="bibr" rid="CR119">119</xref></sup>. The development and efficacy evaluation of therapeutic vaccines targeting the TME and its surrounding immune responses further confirm that virus infiltration within tumors can enhance host responses to initial immunotherapy<sup><xref ref-type="bibr" rid="CR120">120</xref></sup>. Furthermore, considering the proteomic characteristics and immunogenicity of tumor-associated bacteria and viruses, online data atlases represented by MicroEpitope have detailed the correlation between intratumoral microbe-derived epitopes and immune responses in different tumor microenvironments<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. This database systematically integrates proteomic information of tumor-associated bacteria and viruses, exploring microbial immunogenicity and its clinical relevance in depth. For example, in lung cancer, the epitope &#8220;AEMLREEGY&#8221; derived from <italic toggle="yes">Mycobacterium tuberculosis</italic> is recognized by T cells after presentation by HLA-I molecules, effectively inducing T cell immune responses; while in chronic lymphocytic leukemia, the EBV-derived epitope &#8220;LLDFVRFMGV&#8221; can specifically activate cytotoxic T cell responses<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. In conclusion, microbial detection within tumor tissues offers greater advantages in predicting ICI efficacy, but tumor tissue heterogeneity and potential sampling bias must be fully considered.</p><p id="Par19">This meta-analysis indicates that bacterial status and enrichment levels lack overall predictive value for ICI efficacy but show differential associations with outcomes in specific cancers. Subgroup analyses revealed a positive correlation between bacterial status and survival in hepatobiliary and lung cancers, while a negative correlation was observed in gastrointestinal tumors. Several studies have reported compositional differences in gut microbiota between ICI responders and non-responders, underscoring the significant impact of microbiota variability on ICI efficacy<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR122">122</xref>&#8211;<xref ref-type="bibr" rid="CR125">125</xref></sup>. However, the precise relationship between gut bacteria and tumor progression or prognosis remains incompletely understood. Complex host-microbiota interactions are recognized as correlating with cancer progression, with bacterial toxins and metabolites directly activating oncogenic pathways or suppressing immune-regulatory signals, particularly in colorectal cancer<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>. Emerging concepts such as the gut-lung axis<sup><xref ref-type="bibr" rid="CR127">127</xref></sup> and gut-liver axis<sup><xref ref-type="bibr" rid="CR128">128</xref></sup> highlight inter-organ feedback mechanisms mediated by microbiota-immune system interactions. Evidence suggests that dietary interventions and supplementation with probiotics or prebiotics may improve antitumor immune responses<sup><xref ref-type="bibr" rid="CR129">129</xref>,<xref ref-type="bibr" rid="CR130">130</xref></sup>. Furthermore, fecal microbiota transplantation (FMT) from ICI responders has shown potential to restore gut microbial balance and enhance therapeutic efficacy<sup><xref ref-type="bibr" rid="CR131">131</xref>&#8211;<xref ref-type="bibr" rid="CR133">133</xref></sup>. Our preliminary research included 10 clinical studies published up to September 2024, demonstrating that FMT combined with ICIs treatment achieved a 43% ORR, significantly superior to the 20&#8211;40% response rate of single-agent ICIs therapy reported in previous studies, without significantly increasing toxic risk. Further analysis indicated that treatment efficacy potentially correlates with ICI regimens, FMT donor sources, and FMT administration methods<sup><xref ref-type="bibr" rid="CR134">134</xref></sup>. However, FMT&#8217;s efficacy is influenced by variability in beneficial microbial compositions across cohorts and tumor types, presenting a critical challenge for its application in cancer therapy. The differential associations between bacterial enrichment and survival outcomes across tumor types likely arise from the dynamic interactions among bacteria, the host, and the immune system. For gastrointestinal tumors, the included cohorts primarily focused on <italic toggle="yes">Helicobacter pylori</italic>, a known gastric cancer pathogen, which may have increased cohort heterogeneity and introduced selection bias. Indirect effects of bacteria on ICI efficacy may depend not only on their oncogenic or tumor-suppressive properties but also on factors such as host condition, tumor heterogeneity, and sampling site or timing. For example, Wu et al. demonstrated that intratumoral <italic toggle="yes">Streptococcus</italic> predicted responses to combined chemotherapy and ICI therapy in esophageal squamous cell carcinoma (ESCC), proposing that cross-reactivity between bacterial and tumor antigens within the TME, affecting immunotherapy efficacy by increasing the infiltration of granzyme B-positive (GRZB&#8201;+&#8201;) CD8&#8201;+&#8201;T cells in tumors and regulating the ratio between CD8+ Tem and CD4+ Treg<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. Due to the limited sample size and availability of cohorts, most bacterial samples in this meta-analysis were derived from fecal specimens, with fewer from extracellular vesicles or tumor tissues. This limitation in sampling sources may have led to an incomplete assessment of the predictive capacity of bacteria. Future high-quality clinical studies are needed to address confounding factors affecting bacterial predictive power, scientifically evaluate the microbiota&#8217;s role in ICI efficacy, and explore the mechanisms of microbiota-tumor interactions across different cancer types.</p><p id="Par20">This meta-analysis highlights that multi-microbiome combinations exhibit stronger predictive value for ICI efficacy compared to single microbial taxa. The therapeutic effectiveness of ICIs depends on a healthy gut microbiota, which requires microbial diversity and dynamic equilibrium with the immune system<sup><xref ref-type="bibr" rid="CR135">135</xref>,<xref ref-type="bibr" rid="CR136">136</xref></sup>. This complex microbiota-immune regulatory network involves microbial synergy, functional complementarity, metabolite-mediated immune modulation, and microenvironmental remodeling. Numerous studies have shown that increased gut microbiome diversity is closely associated with improved responses to ICIs<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR123">123</xref>,<xref ref-type="bibr" rid="CR137">137</xref>,<xref ref-type="bibr" rid="CR138">138</xref></sup>. Conversely, the use of antibiotics during ICI treatment has been confirmed as an independent risk factor for poor clinical outcomes, likely due to persistent microbiota diversity loss<sup><xref ref-type="bibr" rid="CR139">139</xref>,<xref ref-type="bibr" rid="CR140">140</xref></sup>. However, FMT from ICI responders has demonstrated the ability to restore microbial diversity and re-establish antitumor activity<sup><xref ref-type="bibr" rid="CR139">139</xref>,<xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR142">142</xref></sup>. Despite these findings, some studies have reported conflicting results regarding the direct association between microbiota diversity and ICI efficacy<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. Such discrepancies may arise from cohort heterogeneity, differences in microbiome diversity analysis methods, or inconsistent evaluation criteria. Traditional measurements of species richness and abundance should be complemented by microbial genomic variation analyses for a more comprehensive understanding of diversity. For instance, Liu et al. using metagenomic sequencing, identified highly variable structural variations in microbial genomes, which were associated with ICI treatment outcomes in patients with renal cell carcinoma, non-small cell lung cancer (NSCLC), and melanoma<sup><xref ref-type="bibr" rid="CR144">144</xref></sup>. Similarly, Derosa et al. analyzed the genomic characteristics of fecal samples from advanced NSCLC patients and successfully constructed a species-level co-abundance network. They identified two competing multi-microbiome groups with distinct functional patterns and metabolic pathways. They identified two competing multi-microbiome groups with distinct functional and metabolic patterns, which drove clinical responses to ICIs and demonstrated exceptional predictive value<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. These multi-dimensional studies, integrating metagenomics and functional metabolomics, underscore the critical role of microbiota diversity in predicting ICI efficacy. Moreover, they open new avenues for exploring multi-microbiome interaction networks and the regulatory mechanisms of the tumor-microbiota-immune system axis. Regarding the potential heterogeneity introduced by the choice of transcriptomic or metagenomic sequencing in assessing the predictive value of microbial communities for ICIs, current evidence does not support a significant influence. 16S rRNA sequencing represents the predominant methodological approach for characterizing bacterial community diversity. The relatively conserved nature and manageable amplicon length of the 16S rRNA confers robust analytical stability across high-throughput sample processing workflows. In contrast to 16S rRNA sequencing, whole-genome shotgun metagenomic sequencing provides more comprehensive taxonomic and functional characterization, encompassing broader genomic content and enabling higher-resolution bacterial community profiling. The shotgun metagenome sequencing facilitate identification and characterization of low-abundance viral populations and taxonomically challenging bacterial communities that remain undetectable through single-marker gene methodologies<sup><xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR147">147</xref></sup>. In our analysis, while both widely implemented 16S rRNA and metagenomic sequencing methodologies generated divergent findings regarding microbial community predictive utility for ICI responses, metagenomic approaches demonstrated superior associations with long-term immunotherapeutic outcome prediction. Previous investigations have demonstrated that at higher taxonomic ranks, 16S rRNA and metagenomic sequencing approaches exhibit substantial concordance in alpha diversity metrics, including community richness, evenness indices, and relative abundance distributions<sup><xref ref-type="bibr" rid="CR148">148</xref></sup>. However, these methodologies diverge substantially when characterizing fine-scale diversity patterns and community structural attributes, with shotgun metagenomic approaches offering enhanced taxonomic resolution, sensitivity, and specificity at species-level identification<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>. As investigations evaluating microbiome-based predictive biomarkers for immunotherapeutic efficacy predominantly analyze taxonomic signatures at phylum level and below, the methodological concordance between these sequencing approaches becomes less apparent, although meta-analyses suggest non-significant statistical differences in overall predictive performance. Furthermore, observed discrepancies likely derive from fundamental methodological distinctions between these analytical approaches, including differences in sample preparation, nucleic acid extraction protocols, bioinformatic processing pipelines, and inherent technical biases.</p><p id="Par21">This meta-analysis evaluated the predictive value of viral status for adverse events (AEs) during ICI treatment, revealing that viral status may predict the risk of SAEs in patients with hepatobiliary cancers. Early studies have demonstrated that in patients with chronic HBV infection undergoing ICI therapy, the addition of intensified antiviral treatment can significantly reduce the risk of viral reactivation<sup><xref ref-type="bibr" rid="CR150">150</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup>. This finding provides critical guidance for clinical practice, suggesting that enhanced antiviral therapy could be a key strategy to ensure the safe administration of ICIs in HBV-infected patients. IrAEs are believed to result from immune activation and immune-mediated tissue damage during ICI therapy. However, the relationship between irAEs and viral reactivation remains unclear. Notably, studies have reported that the occurrence of irAEs is associated with increased hepatitis B surface antigen (HBsAg) levels and a higher risk of HBV replication<sup><xref ref-type="bibr" rid="CR152">152</xref></sup>. These observations underscores the need to investigate the causal relationship and interaction mechanisms between irAEs and viral status. A deeper understanding of these dynamics is essential for developing effective strategies to prevent AEs and viral reactivation during ICI therapy. Although research on the relationship between the microbiota and irAEs is limited, emerging evidence suggests a potential link between gut microbiota composition and the development of specific irAEs. For example, recolonization of <italic toggle="yes">Enterobacteriaceae</italic> during ICI treatment has been implicated in increasing intestinal inflammatory toxicity through the expression of inflammatory cytokine IL-1&#946;<sup><xref ref-type="bibr" rid="CR153">153</xref></sup>. This phenomenon is particularly pronounced in dual ICI combination therapies, where it has been associated with an increased incidence of severe AEs<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. These findings suggest that the gut microbiota may play a critical role in the development of irAEs, particularly in the context of combination immunotherapies.</p><p id="Par22">Despite providing significant evidence for the role of the microbiome in predicting tumor response to ICIs, this meta-analysis has several limitations. Firstly, the analysis primarily included moderate- to high-quality cohort studies, with a lack of RCTs. This limitation may reduce the ability to control for confounding factors and restrict causal inference. Secondly, endpoints related to viruses and bacteria was incomplete across the included studies, and there was heterogeneity in the selection of endpoints. Specifically, studies on virus lacked long-term follow-up data, limiting the evaluation of sustained predictive value. Studies on bacteria lacked data on AEs following treatment, which may have hindered a comprehensive assessment of the microbiome&#8217;s predictive capacity for safety outcomes. Furthermore, the presence and enrichment of bacteria were primarily analyzed using binary classifications based on study descriptions, without standardized sequencing analysis or categorization. This approach may oversimplify complex bacterial community states and fail to capture intricate relationships between bacterial diversity and ICI efficacy, potentially underestimating these associations.</p><p id="Par23">This meta-analysis presents preliminary evidence-based findings on the predictive value of the microbiome for ICI efficacy and safety across various cancer types. The results demonstrate that the microbiome has significant predictive potential for ICI outcomes, particularly in monotherapy settings, with notable variations in the associations between distinct viral and bacterial groups and clinical responses across tumor types. Furthermore, this study underscores the potential value of multi-microbiome predictive models while identifying critical gaps in the research on the microbiome&#8217;s role in predicting ICI safety, offering new directions for investigating the interplay between the microbiome and immunotherapy. Despite the limitations of this study, such as the restricted scope of included studies and insufficient depth of subgroup analyses, it systematically summarizes the current applications and future directions for microbiome-based prediction in ICI efficacy. The findings highlight the necessity of conducting large-scale RCTs, standardizing microbiome assessment frameworks and prognostic evaluation criteria, advancing the development of multi-microbiome predictive models, and integrating analyses of host-microbiome interactions. These research priorities are essential for developing optimal strategies and providing robust evidence to clarify the microbiome&#8217;s influence on tumor progression and immunotherapy outcomes, paving the way for more precise and effective applications of microbiome-based biomarkers in cancer immunotherapy.</p></sec><sec id="Sec10"><title>Methods</title><p id="Par24">This meta-analysis was designed and conducted in strict accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. As the study exclusively uses de-identified patient data, it does not require ethical committee approval or informed consent, in compliance with relevant regulations. This study has been registered in PROSPERO(CRD42025630951).</p><sec id="Sec11"><title>Search strategy</title><p id="Par25">To systematically identify studies examining the relationship between the microbiome and ICI efficacy and safety in cancer treatment, a comprehensive search strategy was developed (see Data S<xref rid="MOESM1" ref-type="media">1</xref>). The databases searched included PubMed, Web of Science, Medline, Embase, Cochrane Library, Wiley Online Library, ClinicalTrials(ClinicalTrials.gov, or published on conference abstracts, including the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the American Association of Cancer Research(AACR)) covering the period from January 1, 2014, to October 9, 2024. Only human studies were included, with no restrictions on publication type or language.</p></sec><sec id="Sec12"><title>Eligibility criteria</title><p id="Par26">Three researchers independently performed the literature search, screened titles and abstracts, and conducted full-text evaluations to extract data on treatment efficacy and safety. Discrepancies were resolved through discussions with senior researchers. The inclusion criteria were: (1) RCT or cohort studies involving patients with pathologically confirmed malignancies. (2) Studies including in vivo microbiome profiling with explicit microbiome characteristics. (3) Studies reporting associations between the microbiome and ICI treatment outcomes. At least one of the following efficacy endpoints was required: ORR, DCR, Partial response (PR), Complete response (CR), Stable disease (SD), PFS, OS, and unadjusted hazard ratios (HRs) in univariate analyses. (4) Studies reporting the occurrence of irAEs or SAEs. Exclusion criteria were: (1) Animal studies. (2) Studies lacking data on pre-treatment microbiome profiles and ICI efficacy or safety. (3) Studies without specific microbiome classifications. (4) Studies reporting only adjusted HRs from multivariate analyses.</p></sec><sec id="Sec13"><title>Data extraction</title><p id="Par27">Three researchers independently extracted data, ensuring accuracy through cross-verification. Baseline characteristics included tumor type, ICI regimens, microbial composition, microbiome sample type, and sequencing approaches. For bacterial studies, microbial composition was categorized based on phyla. Grouped studies included monobacterial vs polybacterial studies, focusing on discussing predictive value of single dominant or microbial community. Additionally, a clear distinction was maintained between microbiome-presence vs. microbiome-absence groups and high vs. low microbiome abundance groups. Given the inconsistent thresholds for classifying bacterial abundance across studies, we defined &#8216;high&#8217; as exceeding the study-specific average in our analysis. Outcome variables included treatment efficacy indicators and AE/SAE incidence rates. Studies assessing microbiomes after pre-treatment with proton pump inhibitors (PPIs) or antibiotics were included in the analysis.</p></sec><sec id="Sec14"><title>Risk of bias assessment</title><p id="Par28">The quality of cohort studies was assessed using the Newcastle&#8211;Ottawa Scale (NOS), while RCT risk of bias was evaluated using the Risk of Bias (ROB) tool in RevMan 5.4. Quality assessments were independently conducted by three researchers, with disagreements resolved through consensus. For cohort studies, NOS scores &lt;4 indicated low quality, while &#8805;7 indicated high quality. RCTs were categorized as low, high, or unclear risk of bias (Table <xref rid="MOESM1" ref-type="media">S3</xref> and <xref rid="MOESM1" ref-type="media">S4</xref>). Publication bias, a common issue in meta-analyses, was assessed using funnel plots and Egger&#8217;s test to ensure reliability.</p></sec><sec id="Sec15"><title>Statistical analysis</title><p id="Par29">Meta-analyses were conducted using RevMan (Version 5.4, Cochrane, UK) and R (Version 4.4.1) with packages such as meta (Version 8.0.1), grid (Version 4.4.1), forestplot (Version 3.1.6), and metafor (Version 4.6.0). Primary analyses examined the relative risk (RR) for microbiome-associated ORR and DCR, and HRs for bacteria-associated PFS and OS. Safety analyses focused on AE/SAE incidence rates. Subgroup analyses stratified studies by virus type, cancer type, and ICI regimen for virus-related studies, with ORR and 95% confidence intervals (CIs) extracted as predictive factors. For bacteria-related studies, subgroup analyses were based on bacterial phyla, microbial abundance, cancer type, and sequencing methods, with HRs for PFS and OS used as prognostic indicators. Both fixed-effect and random-effect models were used for pooled analyses, depending on heterogeneity assessed by the Q test and I<sup>2</sup>. Fixed-effect models were applied for I<sup>2</sup>&#8201;&lt;&#8201;50%(low heterogeneity), while random-effect models were used for I<sup>2</sup>&#8201;&gt;&#8201;50%(high heterogeneity). Statistical significance was set at P&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec16" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="41522_2025_819_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Materials</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="41522_2025_819_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>PRISMA_2020_checklist</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Lihaoyun Huang, Yu Li, Chunyan Zhang, Aimin Jiang.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41522-025-00819-2.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by grants from the National Natural Science Foundation of China (82172750); the Guangdong Provincial Medical Science and Technology Research Fund(B2023341).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L.H. wrote the manuscript and prepared all the figures and tables. Y.L., C.Z. and A.J. corrected, collected and organized the related references and revised and finalized the manuscript. L.H., Y.L., C.Z., A.J., L.Z., W.M., A.J., K.L. J.Z. and X.C. researched data for the manuscript. A.L. and P.L. conceived the study content and provided constructive guidance. T.W. inception of study idea and supervision. C.C. and T.W. provided the funding acquisition.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data sharing is not applicable to this article as no new data were created or analyzed in this study. Code Availability: Code sharing is not applicable to this article.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenz</surname><given-names>H-J</given-names></name><etal/></person-group><article-title>First-line Nivolumab plus low-dose Ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkMate 142 study</article-title><source>J. Clin. Oncol.</source><year>2022</year><volume>40</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">34637336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01015</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lenz, H.-J. et al. First-line Nivolumab plus low-dose Ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkMate 142 study. <italic toggle="yes">J. Clin. Oncol.</italic><bold>40</bold>, 161&#8211;170 (2022).<pub-id pub-id-type="pmid">34637336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>1223</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">36166026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.16464</pub-id><pub-id pub-id-type="pmcid">PMC9516323</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cheng, Y. et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. <italic toggle="yes">JAMA</italic><bold>328</bold>, 1223&#8211;1232 (2022).<pub-id pub-id-type="pmid">36166026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.16464</pub-id><pub-id pub-id-type="pmcid">PMC9516323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><etal/></person-group><article-title>CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer</article-title><source>Brief. Bioinform.</source><year>2022</year><volume>23</volume><fpage>bbac129</fpage><pub-id pub-id-type="pmid">35395670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbac129</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lin, A. et al. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. <italic toggle="yes">Brief. Bioinform.</italic><bold>23</bold>, bbac129 (2022).<pub-id pub-id-type="pmid">35395670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbac129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><name name-style="western"><surname>Luo</surname><given-names>P</given-names></name></person-group><article-title>Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies</article-title><source>Curr. Pharm. Anal.</source><year>2024</year><volume>21</volume><fpage>1</fpage><lpage>19</lpage></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Chen, J., Lin, A. &amp; Luo, P. Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies. <italic toggle="yes">Curr. Pharm. Anal.</italic><bold>21</bold>, 1&#8211;19 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>R</given-names></name><etal/></person-group><article-title>MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer</article-title><source>Front. Cell Dev. Biol.</source><year>2022</year><volume>10</volume><fpage>757137</fpage><pub-id pub-id-type="pmid">35223828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2022.757137</pub-id><pub-id pub-id-type="pmcid">PMC8873787</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Yi, R. et al. MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer. <italic toggle="yes">Front. Cell Dev. Biol.</italic><bold>10</bold>, 757137 (2022).<pub-id pub-id-type="pmid">35223828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2022.757137</pub-id><pub-id pub-id-type="pmcid">PMC8873787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><etal/></person-group><article-title>TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>667875</fpage><pub-id pub-id-type="pmid">34603277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.667875</pub-id><pub-id pub-id-type="pmcid">PMC8481577</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lin, A. et al. TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer. <italic toggle="yes">Front. Immunol.</italic><bold>12</bold>, 667875 (2021).<pub-id pub-id-type="pmid">34603277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.667875</pub-id><pub-id pub-id-type="pmcid">PMC8481577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doroshow</surname><given-names>DB</given-names></name><etal/></person-group><article-title>PD-L1 as a biomarker of response to immune-checkpoint inhibitors</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>345</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">33580222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00473-5</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>18</bold>, 345&#8211;362 (2021).<pub-id pub-id-type="pmid">33580222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00473-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dall&#8217;Olio</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Tumour burden and efficacy of immune-checkpoint inhibitors</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2022</year><volume>19</volume><fpage>75</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">34642484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00564-3</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dall&#8217;Olio, F. G. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>19</bold>, 75&#8211;90 (2022).<pub-id pub-id-type="pmid">34642484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00564-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tricarico</surname><given-names>P</given-names></name><etal/></person-group><article-title>Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy</article-title><source>J. Immunother. Cancer</source><year>2024</year><volume>12</volume><fpage>e007628</fpage><pub-id pub-id-type="pmid">38649279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-007628</pub-id><pub-id pub-id-type="pmcid">PMC11043703</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tricarico, P. et al. Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. <italic toggle="yes">J. Immunother. Cancer</italic><bold>12</bold>, e007628 (2024).<pub-id pub-id-type="pmid">38649279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-007628</pub-id><pub-id pub-id-type="pmcid">PMC11043703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>C</given-names></name><etal/></person-group><article-title>The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2022</year><volume>41</volume><fpage>268</fpage><pub-id pub-id-type="pmid">36071479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-022-02469-0</pub-id><pub-id pub-id-type="pmcid">PMC9450390</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Shi, C. et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <italic toggle="yes">J. Exp. Clin. Cancer Res.</italic><bold>41</bold>, 268 (2022).<pub-id pub-id-type="pmid">36071479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-022-02469-0</pub-id><pub-id pub-id-type="pmcid">PMC9450390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>R</given-names></name><etal/></person-group><article-title>ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment</article-title><source>Front. Genet.</source><year>2020</year><volume>11</volume><fpage>933</fpage><pub-id pub-id-type="pmid">32922441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2020.00933</pub-id><pub-id pub-id-type="pmcid">PMC7456912</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yi, R. et al. ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment. <italic toggle="yes">Front. Genet.</italic><bold>11</bold>, 933 (2020).<pub-id pub-id-type="pmid">32922441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2020.00933</pub-id><pub-id pub-id-type="pmcid">PMC7456912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Li, G. et al. Breaking boundaries: Chronic diseases and the frontiers of immune microenvironments. <italic toggle="yes">Med Res</italic>. 10.1002/mdr2.70006 (2025).</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardim</surname><given-names>DL</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A</given-names></name><name name-style="western"><surname>Gagliato</surname><given-names>D</given-names></name><name name-style="western"><surname>de</surname><given-names>M</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>The challenges of tumor mutational burden as an immunotherapy biomarker</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>154</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">33125859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.10.001</pub-id><pub-id pub-id-type="pmcid">PMC7878292</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Jardim, D. L., Goodman, A., Gagliato, D., de, M. &amp; Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. <italic toggle="yes">Cancer Cell</italic><bold>39</bold>, 154&#8211;173 (2021).<pub-id pub-id-type="pmid">33125859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.10.001</pub-id><pub-id pub-id-type="pmcid">PMC7878292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Development of immunotherapy combination strategies in cancer</article-title><source>Cancer Discov.</source><year>2021</year><volume>11</volume><fpage>1368</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">33811048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-20-1209</pub-id><pub-id pub-id-type="pmcid">PMC8178168</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yap, T. A. et al. Development of immunotherapy combination strategies in cancer. <italic toggle="yes">Cancer Discov.</italic><bold>11</bold>, 1368&#8211;1397 (2021).<pub-id pub-id-type="pmid">33811048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-20-1209</pub-id><pub-id pub-id-type="pmcid">PMC8178168</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2021</year><volume>70</volume><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">32653938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-020-02668-8</pub-id><pub-id pub-id-type="pmcid">PMC10992006</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang, J. et al. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. <italic toggle="yes">Cancer Immunol. Immunother.</italic><bold>70</bold>, 137&#8211;151 (2021).<pub-id pub-id-type="pmid">32653938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-020-02668-8</pub-id><pub-id pub-id-type="pmcid">PMC10992006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Song, P., Peng, Z. &amp; Guo, X. Gut microbial metabolites in cancer therapy. <italic toggle="yes">Trends Endocrinol. Metabol</italic>. <bold>36</bold>, 55&#8211;69 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2024.06.016</pub-id><pub-id pub-id-type="pmid">39004537</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillot</surname><given-names>N</given-names></name><etal/></person-group><article-title>Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality</article-title><source>Trends Mol. Med.</source><year>2023</year><volume>29</volume><fpage>897</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">37704493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2023.08.004</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Guillot, N. et al. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality. <italic toggle="yes">Trends Mol. Med.</italic><bold>29</bold>, 897&#8211;911 (2023).<pub-id pub-id-type="pmid">37704493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2023.08.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Unveiling the power of gut microbiome in predicting neoadjuvant immunochemotherapy responses in esophageal squamous cell carcinoma</article-title><source>Research</source><year>2024</year><volume>7</volume><fpage>0529</fpage><pub-id pub-id-type="pmid">39545038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0529</pub-id><pub-id pub-id-type="pmcid">PMC11562848</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu, L. et al. Unveiling the power of gut microbiome in predicting neoadjuvant immunochemotherapy responses in esophageal squamous cell carcinoma. <italic toggle="yes">Research</italic><bold>7</bold>, 0529 (2024).<pub-id pub-id-type="pmid">39545038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0529</pub-id><pub-id pub-id-type="pmcid">PMC11562848</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment</article-title><source>Research</source><year>2024</year><volume>7</volume><fpage>0364</fpage><pub-id pub-id-type="pmid">38721274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0364</pub-id><pub-id pub-id-type="pmcid">PMC11077293</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Li, L. et al. Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment. <italic toggle="yes">Research</italic><bold>7</bold>, 0364 (2024).<pub-id pub-id-type="pmid">38721274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0364</pub-id><pub-id pub-id-type="pmcid">PMC11077293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Gao, Z. et al. Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development. <italic toggle="yes">Med Res</italic>. 10.1002/mdr2.70007 (2025).</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#233;tizou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">26541610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad1329</pub-id><pub-id pub-id-type="pmcid">PMC4721659</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">V&#233;tizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <italic toggle="yes">Science</italic><bold>350</bold>, 1079&#8211;1084 (2015).<pub-id pub-id-type="pmid">26541610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad1329</pub-id><pub-id pub-id-type="pmcid">PMC4721659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">26541606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aac4255</pub-id><pub-id pub-id-type="pmcid">PMC4873287</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. <italic toggle="yes">Science</italic><bold>350</bold>, 1084&#8211;1089 (2015).<pub-id pub-id-type="pmid">26541606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aac4255</pub-id><pub-id pub-id-type="pmcid">PMC4873287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>L</given-names></name><etal/></person-group><article-title>Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients</article-title><source>Eur. Urol.</source><year>2020</year><volume>78</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">32376136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.04.044</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Derosa, L. et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. <italic toggle="yes">Eur. Urol.</italic><bold>78</bold>, 195&#8211;206 (2020).<pub-id pub-id-type="pmid">32376136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.04.044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The gut microbiome is associated with clinical response to Anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer</article-title><source>Cancer Immunol. Res.</source><year>2020</year><volume>8</volume><fpage>1251</fpage><lpage>1261</lpage><pub-id pub-id-type="pmid">32855157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-19-1014</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Peng, Z. et al. The gut microbiome is associated with clinical response to Anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. <italic toggle="yes">Cancer Immunol. Res.</italic><bold>8</bold>, 1251&#8211;1261 (2020).<pub-id pub-id-type="pmid">32855157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-19-1014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC</article-title><source>J. Thorac. Oncol.</source><year>2019</year><volume>14</volume><fpage>1378</fpage><lpage>1389</lpage><pub-id pub-id-type="pmid">31026576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2019.04.007</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. <italic toggle="yes">J. Thorac. Oncol.</italic><bold>14</bold>, 1378&#8211;1389 (2019).<pub-id pub-id-type="pmid">31026576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2019.04.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Routy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">29097494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan3706</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <italic toggle="yes">Science</italic><bold>359</bold>, 91&#8211;97 (2018).<pub-id pub-id-type="pmid">29097494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan3706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Situ</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy</article-title><source>EBioMedicine</source><year>2025</year><volume>115</volume><fpage>105708</fpage><pub-id pub-id-type="pmid">40267755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2025.105708</pub-id><pub-id pub-id-type="pmcid">PMC12052696</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Situ, Y. et al. The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy. <italic toggle="yes">EBioMedicine</italic><bold>115</bold>, 105708 (2025).<pub-id pub-id-type="pmid">40267755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2025.105708</pub-id><pub-id pub-id-type="pmcid">PMC12052696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davar</surname><given-names>D</given-names></name><name name-style="western"><surname>Zarour</surname><given-names>HM</given-names></name></person-group><article-title>Facts and hopes for gut microbiota interventions in cancer immunotherapy</article-title><source>Clin. Cancer Res.</source><year>2022</year><volume>28</volume><fpage>4370</fpage><lpage>4384</lpage><pub-id pub-id-type="pmid">35748749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-1129</pub-id><pub-id pub-id-type="pmcid">PMC9561605</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Davar, D. &amp; Zarour, H. M. Facts and hopes for gut microbiota interventions in cancer immunotherapy. <italic toggle="yes">Clin. Cancer Res.</italic><bold>28</bold>, 4370&#8211;4384 (2022).<pub-id pub-id-type="pmid">35748749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-1129</pub-id><pub-id pub-id-type="pmcid">PMC9561605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goc</surname><given-names>J</given-names></name><name name-style="western"><surname>Sonnenberg</surname><given-names>GF</given-names></name></person-group><article-title>Harnessing microbiota to improve immunotherapy for gastrointestinal cancers</article-title><source>Cancer Immunol. Res.</source><year>2022</year><volume>10</volume><fpage>1292</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">36166399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-22-0164</pub-id><pub-id pub-id-type="pmcid">PMC10424780</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Goc, J. &amp; Sonnenberg, G. F. Harnessing microbiota to improve immunotherapy for gastrointestinal cancers. <italic toggle="yes">Cancer Immunol. Res.</italic><bold>10</bold>, 1292&#8211;1298 (2022).<pub-id pub-id-type="pmid">36166399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-22-0164</pub-id><pub-id pub-id-type="pmcid">PMC10424780</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1432</fpage><lpage>1441</lpage><pub-id pub-id-type="pmid">34239137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01406-6</pub-id><pub-id pub-id-type="pmcid">PMC11107795</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <italic toggle="yes">Nat. Med.</italic><bold>27</bold>, 1432&#8211;1441 (2021).<pub-id pub-id-type="pmid">34239137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01406-6</pub-id><pub-id pub-id-type="pmcid">PMC11107795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustafayev</surname><given-names>K</given-names></name><name name-style="western"><surname>Torres</surname><given-names>H</given-names></name></person-group><article-title>Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies</article-title><source>Clin. Microbiol. Infect.</source><year>2022</year><volume>28</volume><fpage>1321</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">35283317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2022.02.042</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Mustafayev, K. &amp; Torres, H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. <italic toggle="yes">Clin. Microbiol. Infect.</italic><bold>28</bold>, 1321&#8211;1327 (2022).<pub-id pub-id-type="pmid">35283317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2022.02.042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yibirin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors</article-title><source>Am. J. Gastroenterol.</source><year>2023</year><volume>118</volume><fpage>1609</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">37307533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000002361</pub-id><pub-id pub-id-type="pmcid">PMC11809494</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Yibirin, M. et al. Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors. <italic toggle="yes">Am. J. Gastroenterol.</italic><bold>118</bold>, 1609&#8211;1617 (2023).<pub-id pub-id-type="pmid">37307533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000002361</pub-id><pub-id pub-id-type="pmcid">PMC11809494</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z</given-names></name></person-group><article-title>Hepatocellular carcinoma patients with hepatitis B virus infection exhibited favorable survival from immune checkpoint inhibitors: a systematic review and meta-analysis</article-title><source>Liver Cancer</source><year>2024</year><volume>13</volume><fpage>344</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">39021889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000534446</pub-id><pub-id pub-id-type="pmcid">PMC11250578</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Du, Q., Yuan, J. &amp; Ren, Z. Hepatocellular carcinoma patients with hepatitis B virus infection exhibited favorable survival from immune checkpoint inhibitors: a systematic review and meta-analysis. <italic toggle="yes">Liver Cancer</italic><bold>13</bold>, 344&#8211;354 (2024).<pub-id pub-id-type="pmid">39021889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000534446</pub-id><pub-id pub-id-type="pmcid">PMC11250578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies: real-world evidence from a retrospective study using propensity score matching</article-title><source>Medicine</source><year>2021</year><volume>100</volume><fpage>e28113</fpage><pub-id pub-id-type="pmid">34889269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000028113</pub-id><pub-id pub-id-type="pmcid">PMC8663830</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zhong, L. et al. Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies: real-world evidence from a retrospective study using propensity score matching. <italic toggle="yes">Medicine</italic><bold>100</bold>, e28113 (2021).<pub-id pub-id-type="pmid">34889269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000028113</pub-id><pub-id pub-id-type="pmcid">PMC8663830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>977</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">34143971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00252-7</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. <italic toggle="yes">Lancet Oncol.</italic><bold>22</bold>, 977&#8211;990 (2021).<pub-id pub-id-type="pmid">34143971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00252-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>1162</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">34174189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00302-8</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yang, Y. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. <italic toggle="yes">Lancet Oncol.</italic><bold>22</bold>, 1162&#8211;1174 (2021).<pub-id pub-id-type="pmid">34174189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00302-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y-T</given-names></name><etal/></person-group><article-title>PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial</article-title><source>Am. J. Cancer Res.</source><year>2021</year><volume>11</volume><fpage>5006</fpage><lpage>5015</lpage><pub-id pub-id-type="pmid">34765307</pub-id><pub-id pub-id-type="pmcid">PMC8569350</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sun, Y.-T. et al. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. <italic toggle="yes">Am. J. Cancer Res.</italic><bold>11</bold>, 5006&#8211;5015 (2021).<pub-id pub-id-type="pmid">34765307</pub-id><pub-id pub-id-type="pmcid">PMC8569350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004080</fpage><pub-id pub-id-type="pmid">35241494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-004080</pub-id><pub-id pub-id-type="pmcid">PMC8896035</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Bai, Y. et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. <italic toggle="yes">J. Immunother. Cancer</italic><bold>10</bold>, e004080 (2022).<pub-id pub-id-type="pmid">35241494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-004080</pub-id><pub-id pub-id-type="pmcid">PMC8896035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy</article-title><source>Transl. Lung Cancer Res.</source><year>2021</year><volume>10</volume><fpage>3191</fpage><lpage>3202</lpage><pub-id pub-id-type="pmid">34430357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr-21-455</pub-id><pub-id pub-id-type="pmcid">PMC8350074</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zhang, X. et al. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. <italic toggle="yes">Transl. Lung Cancer Res.</italic><bold>10</bold>, 3191&#8211;3202 (2021).<pub-id pub-id-type="pmid">34430357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr-21-455</pub-id><pub-id pub-id-type="pmcid">PMC8350074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study</article-title><source>Lancet Reg. Health West Pac.</source><year>2023</year><volume>31</volume><fpage>100617</fpage><pub-id pub-id-type="pmid">36879786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2022.100617</pub-id><pub-id pub-id-type="pmcid">PMC9985015</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Shi, Y. et al. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. <italic toggle="yes">Lancet Reg. Health West Pac.</italic><bold>31</bold>, 100617 (2023).<pub-id pub-id-type="pmid">36879786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2022.100617</pub-id><pub-id pub-id-type="pmcid">PMC9985015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>W-Z</given-names></name><etal/></person-group><article-title>Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma</article-title><source>Eur. J. Cancer</source><year>2023</year><volume>194</volume><fpage>113337</fpage><pub-id pub-id-type="pmid">37862797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.113337</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">He, W.-Z. et al. Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. <italic toggle="yes">Eur. J. Cancer</italic><bold>194</bold>, 113337 (2023).<pub-id pub-id-type="pmid">37862797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.113337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y-K</given-names></name><etal/></person-group><article-title>Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study</article-title><source>Clin. Transl. Gastroenterol.</source><year>2022</year><volume>13</volume><fpage>e00475</fpage><pub-id pub-id-type="pmid">35297794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ctg.0000000000000475</pub-id><pub-id pub-id-type="pmcid">PMC9132513</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Cheng, Y.-K. et al. Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study. <italic toggle="yes">Clin. Transl. Gastroenterol.</italic><bold>13</bold>, e00475 (2022).<pub-id pub-id-type="pmid">35297794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ctg.0000000000000475</pub-id><pub-id pub-id-type="pmcid">PMC9132513</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Himmelsbach</surname><given-names>V</given-names></name><etal/></person-group><article-title>Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers</article-title><source>Cancers</source><year>2022</year><volume>14</volume><fpage>1722</fpage><pub-id pub-id-type="pmid">35406493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14071722</pub-id><pub-id pub-id-type="pmcid">PMC8996828</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Himmelsbach, V. et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. <italic toggle="yes">Cancers</italic><bold>14</bold>, 1722 (2022).<pub-id pub-id-type="pmid">35406493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14071722</pub-id><pub-id pub-id-type="pmcid">PMC8996828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yau</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>77</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">34914889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00604-5</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Yau, T. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <italic toggle="yes">Lancet Oncol.</italic><bold>23</bold>, 77&#8211;90 (2022).<pub-id pub-id-type="pmid">34914889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00604-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yau</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial</article-title><source>JAMA Oncol.</source><year>2020</year><volume>6</volume><fpage>e204564</fpage><pub-id pub-id-type="pmid">33001135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.4564</pub-id><pub-id pub-id-type="pmcid">PMC7530824</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. <italic toggle="yes">JAMA Oncol.</italic><bold>6</bold>, e204564 (2020).<pub-id pub-id-type="pmid">33001135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.4564</pub-id><pub-id pub-id-type="pmcid">PMC7530824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seiwert</surname><given-names>TY</given-names></name><etal/></person-group><article-title>Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial</article-title><source>Lancet Oncol.</source><year>2016</year><volume>17</volume><fpage>956</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">27247226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(16)30066-3</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <italic toggle="yes">Lancet Oncol.</italic><bold>17</bold>, 956&#8211;965 (2016).<pub-id pub-id-type="pmid">27247226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(16)30066-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramadoss</surname><given-names>T</given-names></name><etal/></person-group><article-title>Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma</article-title><source>J. Immunother. Cancer</source><year>2024</year><volume>12</volume><fpage>e009816</fpage><pub-id pub-id-type="pmid">39242118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2024-009816</pub-id><pub-id pub-id-type="pmcid">PMC11381633</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ramadoss, T. et al. Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. <italic toggle="yes">J. Immunother. Cancer</italic><bold>12</bold>, e009816 (2024).<pub-id pub-id-type="pmid">39242118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2024-009816</pub-id><pub-id pub-id-type="pmcid">PMC11381633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><etal/></person-group><article-title>An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)</article-title><source>Ther. Adv. Med Oncol.</source><year>2022</year><volume>14</volume><fpage>17588359221138380</fpage><pub-id pub-id-type="pmid">36425873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359221138380</pub-id><pub-id pub-id-type="pmcid">PMC9679349</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Lu, S. et al. An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). <italic toggle="yes">Ther. Adv. Med Oncol.</italic><bold>14</bold>, 17588359221138380 (2022).<pub-id pub-id-type="pmid">36425873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359221138380</pub-id><pub-id pub-id-type="pmcid">PMC9679349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Pan, S. et al. Correlation of HBV DNA and Hepatitis B surface antigen levels with tumor response, liver function and immunological indicators in liver cancer patients with hbv infection undergoing PD-1 inhibition combinational therapy. <italic toggle="yes">Front. Immunol</italic>. <bold>13</bold>, 892618 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.892618</pub-id><pub-id pub-id-type="pmcid">PMC9195870</pub-id><pub-id pub-id-type="pmid">35711409</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><fpage>797</fpage><pub-id pub-id-type="pmid">38961378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12564-4</pub-id><pub-id pub-id-type="pmcid">PMC11223362</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Lin, S. et al. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. <italic toggle="yes">BMC Cancer</italic><bold>24</bold>, 797 (2024).<pub-id pub-id-type="pmid">38961378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12564-4</pub-id><pub-id pub-id-type="pmcid">PMC11223362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelley</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): final outcomes of a phase 2 trial</article-title><source>JCO</source><year>2022</year><volume>40</volume><fpage>444</fpage><lpage>444</lpage></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Kelley, R. K. et al. Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): final outcomes of a phase 2 trial. <italic toggle="yes">JCO</italic><bold>40</bold>, 444&#8211;444 (2022). 4_suppl.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection</article-title><source>Eur. J. Cancer</source><year>2018</year><volume>104</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">30347289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2018.09.017</pub-id><pub-id pub-id-type="pmcid">PMC10176037</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Tio, M. et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <italic toggle="yes">Eur. J. Cancer</italic><bold>104</bold>, 137&#8211;144 (2018).<pub-id pub-id-type="pmid">30347289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2018.09.017</pub-id><pub-id pub-id-type="pmcid">PMC10176037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehra</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012</article-title><source>Br. J. Cancer</source><year>2018</year><volume>119</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">29955135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-018-0131-9</pub-id><pub-id pub-id-type="pmcid">PMC6048158</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Mehra, R. et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <italic toggle="yes">Br. J. Cancer</italic><bold>119</bold>, 153&#8211;159 (2018).<pub-id pub-id-type="pmid">29955135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-018-0131-9</pub-id><pub-id pub-id-type="pmcid">PMC6048158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferris</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Nivolumab vs investigator&#8217;s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression</article-title><source>Oral. Oncol.</source><year>2018</year><volume>81</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">29884413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2018.04.008</pub-id><pub-id pub-id-type="pmcid">PMC6563923</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Ferris, R. L. et al. Nivolumab vs investigator&#8217;s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <italic toggle="yes">Oral. Oncol.</italic><bold>81</bold>, 45&#8211;51 (2018).<pub-id pub-id-type="pmid">29884413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2018.04.008</pub-id><pub-id pub-id-type="pmcid">PMC6563923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siu</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Safety and efficacy of Durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">30383184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2018.4628</pub-id><pub-id pub-id-type="pmcid">PMC6439564</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Siu, L. L. et al. Safety and efficacy of Durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. <italic toggle="yes">JAMA Oncol.</italic><bold>5</bold>, 195&#8211;203 (2019).<pub-id pub-id-type="pmid">30383184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2018.4628</pub-id><pub-id pub-id-type="pmcid">PMC6439564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou-Alfa</surname><given-names>GK</given-names></name><etal/></person-group><article-title>Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma</article-title><source>NEJM Evid.</source><year>2022</year><volume>1</volume><fpage>EVIDoa2100070</fpage><pub-id pub-id-type="pmid">38319892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/EVIDoa2100070</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. <italic toggle="yes">NEJM Evid.</italic><bold>1</bold>, EVIDoa2100070 (2022).<pub-id pub-id-type="pmid">38319892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/EVIDoa2100070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Expression and prognostic significance of the PD-1/PD-L1 pathway in AIDS-related non-Hodgkin lymphoma</article-title><source>Cancer Med.</source><year>2024</year><volume>13</volume><fpage>e7195</fpage><pub-id pub-id-type="pmid">38613207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.7195</pub-id><pub-id pub-id-type="pmcid">PMC11015146</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Zhao, H. et al. Expression and prognostic significance of the PD-1/PD-L1 pathway in AIDS-related non-Hodgkin lymphoma. <italic toggle="yes">Cancer Med.</italic><bold>13</bold>, e7195 (2024).<pub-id pub-id-type="pmid">38613207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.7195</pub-id><pub-id pub-id-type="pmcid">PMC11015146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsimafeyeu</surname><given-names>I</given-names></name><etal/></person-group><article-title>Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection</article-title><source>Cancer Immunol. Immunother.</source><year>2020</year><volume>69</volume><fpage>983</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">32078017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-020-02521-y</pub-id><pub-id pub-id-type="pmcid">PMC11027679</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Tsimafeyeu, I. et al. Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. <italic toggle="yes">Cancer Immunol. Immunother.</italic><bold>69</bold>, 983&#8211;988 (2020).<pub-id pub-id-type="pmid">32078017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-020-02521-y</pub-id><pub-id pub-id-type="pmcid">PMC11027679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>L</given-names></name><etal/></person-group><article-title>Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors</article-title><source>ESMO Open</source><year>2022</year><volume>7</volume><fpage>100500</fpage><pub-id pub-id-type="pmid">35753086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2022.100500</pub-id><pub-id pub-id-type="pmcid">PMC9434139</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Rojas, L. et al. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors. <italic toggle="yes">ESMO Open</italic><bold>7</bold>, 100500 (2022).<pub-id pub-id-type="pmid">35753086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2022.100500</pub-id><pub-id pub-id-type="pmcid">PMC9434139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: a retrospective study in China</article-title><source>Front. Genet.</source><year>2022</year><volume>13</volume><fpage>1000448</fpage><pub-id pub-id-type="pmid">36160021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.1000448</pub-id><pub-id pub-id-type="pmcid">PMC9500546</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Liu, H. et al. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: a retrospective study in China. <italic toggle="yes">Front. Genet.</italic><bold>13</bold>, 1000448 (2022).<pub-id pub-id-type="pmid">36160021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.1000448</pub-id><pub-id pub-id-type="pmcid">PMC9500546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Frameshift events predict anti-PD-1/L1 response in head and neck cancer</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><fpage>e98811</fpage><pub-id pub-id-type="pmid">29467336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.98811</pub-id><pub-id pub-id-type="pmcid">PMC5916245</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Hanna, G. J. et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. <italic toggle="yes">JCI Insight</italic><bold>3</bold>, e98811 (2018.<pub-id pub-id-type="pmid">29467336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.98811</pub-id><pub-id pub-id-type="pmcid">PMC5916245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>LQM</given-names></name><etal/></person-group><article-title>Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>3838</fpage><lpage>3845</lpage><pub-id pub-id-type="pmid">27646946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.68.1478</pub-id><pub-id pub-id-type="pmcid">PMC6804896</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chow, L. Q. M. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. <italic toggle="yes">J. Clin. Oncol.</italic><bold>34</bold>, 3838&#8211;3845 (2016).<pub-id pub-id-type="pmid">27646946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.68.1478</pub-id><pub-id pub-id-type="pmcid">PMC6804896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauml</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">28328302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.70.1524</pub-id><pub-id pub-id-type="pmcid">PMC5946724</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Bauml, J. et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. <italic toggle="yes">J. Clin. Oncol.</italic><bold>35</bold>, 1542&#8211;1549 (2017).<pub-id pub-id-type="pmid">28328302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.70.1524</pub-id><pub-id pub-id-type="pmcid">PMC5946724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>G</given-names></name><etal/></person-group><article-title>Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study</article-title><source>Ann. Transl. Med.</source><year>2021</year><volume>9</volume><fpage>1412</fpage><pub-id pub-id-type="pmid">34733964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-21-3020</pub-id><pub-id pub-id-type="pmcid">PMC8506751</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Yuan, G. et al. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. <italic toggle="yes">Ann. Transl. Med.</italic><bold>9</bold>, 1412 (2021).<pub-id pub-id-type="pmid">34733964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-21-3020</pub-id><pub-id pub-id-type="pmcid">PMC8506751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study</article-title><source>Transl. Lung Cancer Res.</source><year>2021</year><volume>10</volume><fpage>1819</fpage><lpage>1828</lpage><pub-id pub-id-type="pmid">34012795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr-21-79</pub-id><pub-id pub-id-type="pmcid">PMC8107742</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Xu, F. et al. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. <italic toggle="yes">Transl. Lung Cancer Res.</italic><bold>10</bold>, 1819&#8211;1828 (2021).<pub-id pub-id-type="pmid">34012795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr-21-79</pub-id><pub-id pub-id-type="pmcid">PMC8107742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zandberg</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with &#8805;25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy</article-title><source>Eur. J. Cancer</source><year>2019</year><volume>107</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">30576970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2018.11.015</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Zandberg, D. P. et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with &#8805;25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. <italic toggle="yes">Eur. J. Cancer</italic><bold>107</bold>, 142&#8211;152 (2019).<pub-id pub-id-type="pmid">30576970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2018.11.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial</article-title><source>Lancet Reg. Health West Pac.</source><year>2023</year><volume>40</volume><fpage>100898</fpage><pub-id pub-id-type="pmid">37701718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2023.100898</pub-id><pub-id pub-id-type="pmcid">PMC10493598</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Chiang, C. L. et al. Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial. <italic toggle="yes">Lancet Reg. Health West Pac.</italic><bold>40</bold>, 100898 (2023).<pub-id pub-id-type="pmid">37701718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2023.100898</pub-id><pub-id pub-id-type="pmcid">PMC10493598</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C</given-names></name><etal/></person-group><article-title>The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>949941</fpage><pub-id pub-id-type="pmid">36457494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.949941</pub-id><pub-id pub-id-type="pmcid">PMC9705955</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Chang, C. et al. The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer. <italic toggle="yes">Front. Oncol.</italic><bold>12</bold>, 949941 (2022).<pub-id pub-id-type="pmid">36457494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.949941</pub-id><pub-id pub-id-type="pmcid">PMC9705955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical outcomes and prognosis factors of Nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor in multi-line therapy for recurrent hepatitis B virus-related hepatocellular carcinoma: a retrospective analysis</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><fpage>1404</fpage><pub-id pub-id-type="pmid">32983970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.01404</pub-id><pub-id pub-id-type="pmcid">PMC7479184</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Chen, C. et al. Clinical outcomes and prognosis factors of Nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor in multi-line therapy for recurrent hepatitis B virus-related hepatocellular carcinoma: a retrospective analysis. <italic toggle="yes">Front. Oncol.</italic><bold>10</bold>, 1404 (2020).<pub-id pub-id-type="pmid">32983970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.01404</pub-id><pub-id pub-id-type="pmcid">PMC7479184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangro</surname><given-names>B</given-names></name><etal/></person-group><article-title>A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C</article-title><source>J. Hepatol.</source><year>2013</year><volume>59</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23466307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2013.02.022</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Sangro, B. et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <italic toggle="yes">J. Hepatol.</italic><bold>59</bold>, 81&#8211;88 (2013).<pub-id pub-id-type="pmid">23466307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2013.02.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pertejo-Fernandez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection</article-title><source>Lung Cancer</source><year>2020</year><volume>145</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">32423643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2020.02.013</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Pertejo-Fernandez, A. et al. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <italic toggle="yes">Lung Cancer</italic><bold>145</bold>, 181&#8211;185 (2020).<pub-id pub-id-type="pmid">32423643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2020.02.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gopalakrishnan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">29097493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan4236</pub-id><pub-id pub-id-type="pmcid">PMC5827966</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <italic toggle="yes">Science</italic><bold>359</bold>, 97&#8211;103 (2018).<pub-id pub-id-type="pmid">29097493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan4236</pub-id><pub-id pub-id-type="pmcid">PMC5827966</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grenda</surname><given-names>A</given-names></name><etal/></person-group><article-title>Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer</article-title><source>AMB Express</source><year>2022</year><volume>12</volume><fpage>86</fpage><pub-id pub-id-type="pmid">35792976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13568-022-01428-4</pub-id><pub-id pub-id-type="pmcid">PMC9259768</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Grenda, A. et al. Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer. <italic toggle="yes">AMB Express</italic><bold>12</bold>, 86 (2022).<pub-id pub-id-type="pmid">35792976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13568-022-01428-4</pub-id><pub-id pub-id-type="pmcid">PMC9259768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma</article-title><source>J. Immunother. Cancer</source><year>2024</year><volume>12</volume><fpage>e008686</fpage><pub-id pub-id-type="pmid">38844407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-008686</pub-id><pub-id pub-id-type="pmcid">PMC11163665</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Zhu, C. et al. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. <italic toggle="yes">J. Immunother. Cancer</italic><bold>12</bold>, e008686 (2024).<pub-id pub-id-type="pmid">38844407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-008686</pub-id><pub-id pub-id-type="pmcid">PMC11163665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer</article-title><source>Biomark. Res.</source><year>2024</year><volume>12</volume><fpage>56</fpage><pub-id pub-id-type="pmid">38831368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-024-00607-8</pub-id><pub-id pub-id-type="pmcid">PMC11149318</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Zhu, C. et al. Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer. <italic toggle="yes">Biomark. Res.</italic><bold>12</bold>, 56 (2024).<pub-id pub-id-type="pmid">38831368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-024-00607-8</pub-id><pub-id pub-id-type="pmcid">PMC11149318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frankel</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Metagenomic Shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients</article-title><source>Neoplasia</source><year>2017</year><volume>19</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">28923537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2017.08.004</pub-id><pub-id pub-id-type="pmcid">PMC5602478</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Frankel, A. E. et al. Metagenomic Shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. <italic toggle="yes">Neoplasia</italic><bold>19</bold>, 848&#8211;855 (2017).<pub-id pub-id-type="pmid">28923537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2017.08.004</pub-id><pub-id pub-id-type="pmcid">PMC5602478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elkrief</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intratumoral <italic toggle="yes">Escherichia</italic> is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small-cell lung cancer</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>3339</fpage><lpage>3349</lpage><pub-id pub-id-type="pmid">39038258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.01488</pub-id><pub-id pub-id-type="pmcid">PMC11600405</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Elkrief, A. et al. Intratumoral <italic toggle="yes">Escherichia</italic> is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small-cell lung cancer. <italic toggle="yes">J. Clin. Oncol.</italic><bold>42</bold>, 3339&#8211;3349 (2024).<pub-id pub-id-type="pmid">39038258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.01488</pub-id><pub-id pub-id-type="pmcid">PMC11600405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dora</surname><given-names>D</given-names></name><etal/></person-group><article-title>Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status</article-title><source>Oncoimmunology</source><year>2023</year><volume>12</volume><fpage>2204746</fpage><pub-id pub-id-type="pmid">37197440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2023.2204746</pub-id><pub-id pub-id-type="pmcid">PMC10184596</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Dora, D. et al. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. <italic toggle="yes">Oncoimmunology</italic><bold>12</bold>, 2204746 (2023).<pub-id pub-id-type="pmid">37197440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2023.2204746</pub-id><pub-id pub-id-type="pmcid">PMC10184596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casadei</surname><given-names>B</given-names></name><etal/></person-group><article-title>Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study</article-title><source>Hematol. Oncol.</source><year>2024</year><volume>42</volume><fpage>e3301</fpage><pub-id pub-id-type="pmid">39104142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hon.3301</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Casadei, B. et al. Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study. <italic toggle="yes">Hematol. Oncol.</italic><bold>42</bold>, e3301 (2024).<pub-id pub-id-type="pmid">39104142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hon.3301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>L</given-names></name><etal/></person-group><article-title>Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">35115705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01655-5</pub-id><pub-id pub-id-type="pmcid">PMC9330544</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <italic toggle="yes">Nat. Med.</italic><bold>28</bold>, 315&#8211;324 (2022).<pub-id pub-id-type="pmid">35115705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01655-5</pub-id><pub-id pub-id-type="pmcid">PMC9330544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients</article-title><source>Cancer Med.</source><year>2023</year><volume>12</volume><fpage>6325</fpage><lpage>6336</lpage><pub-id pub-id-type="pmid">36205311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.5312</pub-id><pub-id pub-id-type="pmcid">PMC10028067</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Zhao, H. et al. Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. <italic toggle="yes">Cancer Med.</italic><bold>12</bold>, 6325&#8211;6336 (2023).<pub-id pub-id-type="pmid">36205311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.5312</pub-id><pub-id pub-id-type="pmcid">PMC10028067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Analysis of the gut microbiota: an emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>2514</fpage><pub-id pub-id-type="pmid">34063829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13112514</pub-id><pub-id pub-id-type="pmcid">PMC8196639</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Zhang, F. et al. Analysis of the gut microbiota: an emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer. <italic toggle="yes">Cancers</italic><bold>13</bold>, 2514 (2021).<pub-id pub-id-type="pmid">34063829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13112514</pub-id><pub-id pub-id-type="pmcid">PMC8196639</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><etal/></person-group><article-title>The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms</article-title><source>Cancer Biol. Med.</source><year>2021</year><volume>18</volume><fpage>1040</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">33960176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2020.0450</pub-id><pub-id pub-id-type="pmcid">PMC8610161</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Yin, H. et al. The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. <italic toggle="yes">Cancer Biol. Med.</italic><bold>18</bold>, 1040&#8211;52 (2021).<pub-id pub-id-type="pmid">33960176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2020.0450</pub-id><pub-id pub-id-type="pmcid">PMC8610161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100383</fpage><pub-id pub-id-type="pmid">34622226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2021.100383</pub-id><pub-id pub-id-type="pmcid">PMC8484502</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Wang, F. et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <italic toggle="yes">Cell Rep. Med.</italic><bold>2</bold>, 100383 (2021).<pub-id pub-id-type="pmid">34622226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2021.100383</pub-id><pub-id pub-id-type="pmcid">PMC8484502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoji</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer</article-title><source>Front. Mol. Biosci.</source><year>2022</year><volume>9</volume><fpage>1040424</fpage><pub-id pub-id-type="pmid">36353732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2022.1040424</pub-id><pub-id pub-id-type="pmcid">PMC9638091</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Shoji, F. et al. Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. <italic toggle="yes">Front. Mol. Biosci.</italic><bold>9</bold>, 1040424 (2022).<pub-id pub-id-type="pmid">36353732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2022.1040424</pub-id><pub-id pub-id-type="pmcid">PMC9638091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Che</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><fpage>904</fpage><pub-id pub-id-type="pmid">35986342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-10004-9</pub-id><pub-id pub-id-type="pmcid">PMC9389789</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Che, H. et al. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. <italic toggle="yes">BMC Cancer</italic><bold>22</bold>, 904 (2022).<pub-id pub-id-type="pmid">35986342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-10004-9</pub-id><pub-id pub-id-type="pmcid">PMC9389789</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade</article-title><source>Eur. J. Cancer</source><year>2022</year><volume>172</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">35780526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.06.002</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Takada, K. et al. Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. <italic toggle="yes">Eur. J. Cancer</italic><bold>172</bold>, 199&#8211;208 (2022).<pub-id pub-id-type="pmid">35780526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.06.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fluctuations in gut microbiome composition during immune checkpoint inhibitor therapy</article-title><source>World J. Oncol.</source><year>2023</year><volume>14</volume><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">37350807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14740/wjon1587</pub-id><pub-id pub-id-type="pmcid">PMC10284636</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Sarkar, J. et al. Fluctuations in gut microbiome composition during immune checkpoint inhibitor therapy. <italic toggle="yes">World J. Oncol.</italic><bold>14</bold>, 178&#8211;187 (2023).<pub-id pub-id-type="pmid">37350807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14740/wjon1587</pub-id><pub-id pub-id-type="pmcid">PMC10284636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCulloch</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>545</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">35228752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01698-2</pub-id><pub-id pub-id-type="pmcid">PMC10246505</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. <italic toggle="yes">Nat. Med.</italic><bold>28</bold>, 545&#8211;556 (2022).<pub-id pub-id-type="pmid">35228752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01698-2</pub-id><pub-id pub-id-type="pmcid">PMC10246505</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>e003334</fpage><pub-id pub-id-type="pmid">34873013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-003334</pub-id><pub-id pub-id-type="pmcid">PMC8650503</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Mao, J. et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. <italic toggle="yes">J. Immunother. Cancer</italic><bold>9</bold>, e003334 (2021).<pub-id pub-id-type="pmid">34873013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-003334</pub-id><pub-id pub-id-type="pmcid">PMC8650503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jingushi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients</article-title><source>Cancer Immunol. Immunother.</source><year>2022</year><volume>71</volume><fpage>2999</fpage><lpage>3011</lpage><pub-id pub-id-type="pmid">35598195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-022-03213-5</pub-id><pub-id pub-id-type="pmcid">PMC10991951</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Jingushi, K. et al. Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients. <italic toggle="yes">Cancer Immunol. Immunother.</italic><bold>71</bold>, 2999&#8211;3011 (2022).<pub-id pub-id-type="pmid">35598195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-022-03213-5</pub-id><pub-id pub-id-type="pmcid">PMC10991951</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tonneau</surname><given-names>M</given-names></name><etal/></person-group><article-title>Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors</article-title><source>Oncoimmunology</source><year>2022</year><volume>11</volume><fpage>2096535</fpage><pub-id pub-id-type="pmid">35832043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2022.2096535</pub-id><pub-id pub-id-type="pmcid">PMC9272833</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Tonneau, M. et al. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. <italic toggle="yes">Oncoimmunology</italic><bold>11</bold>, 2096535 (2022).<pub-id pub-id-type="pmid">35832043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2022.2096535</pub-id><pub-id pub-id-type="pmcid">PMC9272833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>K</given-names></name><etal/></person-group><article-title>Helicobacter pylori and immunotherapy for gastrointestinal cancer</article-title><source>Innovation</source><year>2024</year><volume>5</volume><fpage>100561</fpage><pub-id pub-id-type="pmid">38379784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2023.100561</pub-id><pub-id pub-id-type="pmcid">PMC10878118</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Jia, K. et al. Helicobacter pylori and immunotherapy for gastrointestinal cancer. <italic toggle="yes">Innovation</italic><bold>5</bold>, 100561 (2024).<pub-id pub-id-type="pmid">38379784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2023.100561</pub-id><pub-id pub-id-type="pmcid">PMC10878118</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>7187</fpage><pub-id pub-id-type="pmid">39168966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-49842-5</pub-id><pub-id pub-id-type="pmcid">PMC11339264</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Zhang, M. et al. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. <italic toggle="yes">Nat. Commun.</italic><bold>15</bold>, 7187 (2024).<pub-id pub-id-type="pmid">39168966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-49842-5</pub-id><pub-id pub-id-type="pmcid">PMC11339264</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors</article-title><source>Oncoimmunology</source><year>2022</year><volume>11</volume><fpage>2081010</fpage><pub-id pub-id-type="pmid">35655708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2022.2081010</pub-id><pub-id pub-id-type="pmcid">PMC9154751</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Tomita, Y. et al. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. <italic toggle="yes">Oncoimmunology</italic><bold>11</bold>, 2081010 (2022).<pub-id pub-id-type="pmid">35655708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2022.2081010</pub-id><pub-id pub-id-type="pmcid">PMC9154751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oster</surname><given-names>P</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">34253574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-323392</pub-id><pub-id pub-id-type="pmcid">PMC8862014</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Oster, P. et al. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. <italic toggle="yes">Gut</italic><bold>71</bold>, 457&#8211;466 (2022).<pub-id pub-id-type="pmid">34253574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-323392</pub-id><pub-id pub-id-type="pmcid">PMC8862014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magahis</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors</article-title><source>J. Immunother. Cancer</source><year>2023</year><volume>11</volume><fpage>e007699</fpage><pub-id pub-id-type="pmid">37899129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-007699</pub-id><pub-id pub-id-type="pmcid">PMC10619027</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Magahis, P. T. et al. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. <italic toggle="yes">J. Immunother. Cancer</italic><bold>11</bold>, e007699 (2023).<pub-id pub-id-type="pmid">37899129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-007699</pub-id><pub-id pub-id-type="pmcid">PMC10619027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><etal/></person-group><article-title>Eubacterium rectale improves the efficacy of Anti-PD1 immunotherapy in melanoma via l-Serine-Mediated NK cell activation</article-title><source>Research</source><year>2023</year><volume>6</volume><fpage>0127</fpage><pub-id pub-id-type="pmid">37223471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0127</pub-id><pub-id pub-id-type="pmcid">PMC10202379</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Liu, N. et al. Eubacterium rectale improves the efficacy of Anti-PD1 immunotherapy in melanoma via l-Serine-Mediated NK cell activation. <italic toggle="yes">Research</italic><bold>6</bold>, 0127 (2023).<pub-id pub-id-type="pmid">37223471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0127</pub-id><pub-id pub-id-type="pmcid">PMC10202379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakozaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer</article-title><source>Cancer Immunol. Res.</source><year>2020</year><volume>8</volume><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">32847937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-20-0196</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Hakozaki, T. et al. The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer. <italic toggle="yes">Cancer Immunol. Res.</italic><bold>8</bold>, 1243&#8211;1250 (2020).<pub-id pub-id-type="pmid">32847937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-20-0196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaput</surname><given-names>N</given-names></name><etal/></person-group><article-title>Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab</article-title><source>Ann. Oncol.</source><year>2017</year><volume>28</volume><fpage>1368</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">28368458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdx108</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <italic toggle="yes">Ann. Oncol.</italic><bold>28</bold>, 1368&#8211;1379 (2017).<pub-id pub-id-type="pmid">28368458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdx108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katayama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer</article-title><source>Transl. Lung Cancer Res.</source><year>2019</year><volume>8</volume><fpage>847</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">32010563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2019.10.23</pub-id><pub-id pub-id-type="pmcid">PMC6976345</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Katayama, Y. et al. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <italic toggle="yes">Transl. Lung Cancer Res.</italic><bold>8</bold>, 847&#8211;853 (2019).<pub-id pub-id-type="pmid">32010563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2019.10.23</pub-id><pub-id pub-id-type="pmcid">PMC6976345</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>G</given-names></name><etal/></person-group><article-title>Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression</article-title><source>Cell Discov.</source><year>2020</year><volume>6</volume><fpage>90</fpage><pub-id pub-id-type="pmid">33298893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-00214-5</pub-id><pub-id pub-id-type="pmcid">PMC7721904</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Song, G. et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. <italic toggle="yes">Cell Discov.</italic><bold>6</bold>, 90 (2020).<pub-id pub-id-type="pmid">33298893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-00214-5</pub-id><pub-id pub-id-type="pmcid">PMC7721904</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>HPVTIMER: a shiny web application for tumor immune estimation in human papillomavirus-associated cancers</article-title><source>iMeta</source><year>2023</year><volume>2</volume><fpage>e130</fpage><pub-id pub-id-type="pmid">38867938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/imt2.130</pub-id><pub-id pub-id-type="pmcid">PMC10989930</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Liu, L. et al. HPVTIMER: a shiny web application for tumor immune estimation in human papillomavirus-associated cancers. <italic toggle="yes">iMeta</italic><bold>2</bold>, e130 (2023).<pub-id pub-id-type="pmid">38867938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/imt2.130</pub-id><pub-id pub-id-type="pmcid">PMC10989930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>1825</fpage><lpage>1840.e7</lpage><pub-id pub-id-type="pmid">34270940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2021.06.013</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Cheng, Y. et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. <italic toggle="yes">Immunity</italic><bold>54</bold>, 1825&#8211;1840.e7 (2021).<pub-id pub-id-type="pmid">34270940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2021.06.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer</article-title><source>Cancer Cell</source><year>2025</year><volume>43</volume><fpage>248</fpage><lpage>268.e9</lpage><pub-id pub-id-type="pmid">39889705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2025.01.001</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Guo, X. et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. <italic toggle="yes">Cancer Cell</italic><bold>43</bold>, 248&#8211;268.e9 (2025).<pub-id pub-id-type="pmid">39889705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2025.01.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tosi</surname><given-names>A</given-names></name><etal/></person-group><article-title>The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na&#239;ve tumors with immune checkpoint inhibitors</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2022</year><volume>41</volume><fpage>279</fpage><pub-id pub-id-type="pmid">36123711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-022-02481-4</pub-id><pub-id pub-id-type="pmcid">PMC9487049</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Tosi, A. et al. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na&#239;ve tumors with immune checkpoint inhibitors. <italic toggle="yes">J. Exp. Clin. Cancer Res.</italic><bold>41</bold>, 279 (2022).<pub-id pub-id-type="pmid">36123711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-022-02481-4</pub-id><pub-id pub-id-type="pmcid">PMC9487049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>BH</given-names></name><etal/></person-group><article-title>Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response</article-title><source>Mol. Cancer</source><year>2025</year><volume>24</volume><fpage>3</fpage><pub-id pub-id-type="pmid">39757146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-02191-9</pub-id><pub-id pub-id-type="pmcid">PMC11702232</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Jenkins, B. H. et al. Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response. <italic toggle="yes">Mol. Cancer</italic><bold>24</bold>, 3 (2025).<pub-id pub-id-type="pmid">39757146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-02191-9</pub-id><pub-id pub-id-type="pmcid">PMC11702232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>e000394</fpage><pub-id pub-id-type="pmid">32303615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2019-000394</pub-id><pub-id pub-id-type="pmcid">PMC7204805</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Ho, W. J. et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. <italic toggle="yes">J. Immunother. Cancer</italic><bold>8</bold>, e000394 (2020).<pub-id pub-id-type="pmid">32303615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2019-000394</pub-id><pub-id pub-id-type="pmcid">PMC7204805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Cytokine-mediated immunopathogenesis of Hepatitis B virus infections</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2016</year><volume>50</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">25480494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-014-8465-4</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Li, X., Liu, X., Tian, L. &amp; Chen, Y. Cytokine-mediated immunopathogenesis of Hepatitis B virus infections. <italic toggle="yes">Clin. Rev. Allergy Immunol.</italic><bold>50</bold>, 41&#8211;54 (2016).<pub-id pub-id-type="pmid">25480494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-014-8465-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMiller</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy</article-title><source>J. Immunother. Cancer</source><year>2024</year><volume>12</volume><fpage>e010201</fpage><pub-id pub-id-type="pmid">39572160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2024-010201</pub-id><pub-id pub-id-type="pmcid">PMC11580252</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">McMiller, T. L. et al. Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy. <italic toggle="yes">J. Immunother. Cancer</italic><bold>12</bold>, e010201 (2024).<pub-id pub-id-type="pmid">39572160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2024-010201</pub-id><pub-id pub-id-type="pmcid">PMC11580252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>M-Z</given-names></name><etal/></person-group><article-title>Dynamic single-cell mapping unveils Epstein&#8210;Barr virus-imprinted T-cell exhaustion and on-treatment response</article-title><source>Signal Transduct. Target Ther.</source><year>2023</year><volume>8</volume><fpage>370</fpage><pub-id pub-id-type="pmid">37735150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01622-1</pub-id><pub-id pub-id-type="pmcid">PMC10514267</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Qiu, M.-Z. et al. Dynamic single-cell mapping unveils Epstein&#8210;Barr virus-imprinted T-cell exhaustion and on-treatment response. <italic toggle="yes">Signal Transduct. Target Ther.</italic><bold>8</bold>, 370 (2023).<pub-id pub-id-type="pmid">37735150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01622-1</pub-id><pub-id pub-id-type="pmcid">PMC10514267</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>866</fpage><pub-id pub-id-type="pmid">35165282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-28479-2</pub-id><pub-id pub-id-type="pmcid">PMC8844414</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Wang, J. et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 866 (2022).<pub-id pub-id-type="pmid">35165282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-28479-2</pub-id><pub-id pub-id-type="pmcid">PMC8844414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Epstein-Barr Virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate Interleukin-10 production from monocytes</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>7333</fpage><lpage>7342</lpage><pub-id pub-id-type="pmid">21543473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00182-11</pub-id><pub-id pub-id-type="pmcid">PMC3126557</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Lee, C.-H. et al. Epstein-Barr Virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate Interleukin-10 production from monocytes. <italic toggle="yes">J. Virol.</italic><bold>85</bold>, 7333&#8211;7342 (2011).<pub-id pub-id-type="pmid">21543473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00182-11</pub-id><pub-id pub-id-type="pmcid">PMC3126557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>WY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>The role of gut microbiota in cancer treatment: friend or foe?</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>1867</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">32759302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-321153</pub-id><pub-id pub-id-type="pmcid">PMC7497589</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Cheng, W. Y., Wu, C.-Y. &amp; Yu, J. The role of gut microbiota in cancer treatment: friend or foe?. <italic toggle="yes">Gut</italic><bold>69</bold>, 1867&#8211;1876 (2020).<pub-id pub-id-type="pmid">32759302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-321153</pub-id><pub-id pub-id-type="pmcid">PMC7497589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battaglia</surname><given-names>TW</given-names></name><etal/></person-group><article-title>A pan-cancer analysis of the microbiome in metastatic cancer</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>2324</fpage><lpage>2335.e19</lpage><pub-id pub-id-type="pmid">38599211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.03.021</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Battaglia, T. W. et al. A pan-cancer analysis of the microbiome in metastatic cancer. <italic toggle="yes">Cell</italic><bold>187</bold>, 2324&#8211;2335.e19 (2024).<pub-id pub-id-type="pmid">38599211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.03.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Intratumoral fusobacterium nucleatum recruits tumor-associated neutrophils to promote gastric cancer progression and immune evasion</article-title><source>Cancer Res.</source><year>2025</year><volume>85</volume><fpage>1819</fpage><lpage>1841</lpage><pub-id pub-id-type="pmid">39992708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-24-2580</pub-id><pub-id pub-id-type="pmcid">PMC12079103</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Zhang, T. et al. Intratumoral fusobacterium nucleatum recruits tumor-associated neutrophils to promote gastric cancer progression and immune evasion. <italic toggle="yes">Cancer Res.</italic><bold>85</bold>, 1819&#8211;1841 (2025).<pub-id pub-id-type="pmid">39992708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-24-2580</pub-id><pub-id pub-id-type="pmcid">PMC12079103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>3131</fpage><lpage>3144</lpage><pub-id pub-id-type="pmid">37433041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-22-2593</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Wu, H. et al. Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma. <italic toggle="yes">Cancer Res.</italic><bold>83</bold>, 3131&#8211;3144 (2023).<pub-id pub-id-type="pmid">37433041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-22-2593</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma</article-title><source>Sci. Adv.</source><year>2025</year><volume>11</volume><fpage>eadu1727</fpage><pub-id pub-id-type="pmid">40203108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adu1727</pub-id><pub-id pub-id-type="pmcid">PMC11980860</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Mou, W. et al. Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma. <italic toggle="yes">Sci. Adv.</italic><bold>11</bold>, eadu1727 (2025).<pub-id pub-id-type="pmid">40203108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adu1727</pub-id><pub-id pub-id-type="pmcid">PMC11980860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TS</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>E</given-names></name><name name-style="western"><surname>Coit</surname><given-names>DG</given-names></name><name name-style="western"><surname>Tang</surname><given-names>LH</given-names></name></person-group><article-title>Intratumoral immune response to gastric cancer varies by molecular and histologic subtype</article-title><source>Am. J. Surg. Pathol.</source><year>2019</year><volume>43</volume><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">30969179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000001253</pub-id><pub-id pub-id-type="pmcid">PMC6867704</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Kim, T. S., da Silva, E., Coit, D. G. &amp; Tang, L. H. Intratumoral immune response to gastric cancer varies by molecular and histologic subtype. <italic toggle="yes">Am. J. Surg. Pathol.</italic><bold>43</bold>, 851&#8211;860 (2019).<pub-id pub-id-type="pmid">30969179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000001253</pub-id><pub-id pub-id-type="pmcid">PMC6867704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Heterologous prime-boost with an mRNA vaccine and an oncolytic virus enhances tumor regression through overcoming intratumoral immune suppression</article-title><source>Cell Rep</source><year>2025</year><volume>44</volume><fpage>115745</fpage><pub-id pub-id-type="pmid">40411783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2025.115745</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Zhang, K. et al. Heterologous prime-boost with an mRNA vaccine and an oncolytic virus enhances tumor regression through overcoming intratumoral immune suppression. <italic toggle="yes">Cell Rep</italic>. <bold>44</bold>, 115745 (2025).<pub-id pub-id-type="pmid">40411783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2025.115745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>MicroEpitope: an atlas of immune epitopes derived from cancer microbiomes</article-title><source>Nucleic Acids Res.</source><year>2024</year><volume>53</volume><fpage>D1435</fpage><lpage>D1442</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae877</pub-id><pub-id pub-id-type="pmcid">PMC11701614</pub-id><pub-id pub-id-type="pmid">39380496</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Li, D. et al. MicroEpitope: an atlas of immune epitopes derived from cancer microbiomes. <italic toggle="yes">Nucleic Acids Res.</italic><bold>53</bold>, D1435&#8211;D1442 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae877</pub-id><pub-id pub-id-type="pmcid">PMC11701614</pub-id><pub-id pub-id-type="pmid">39380496</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>P-C</given-names></name><etal/></person-group><article-title>Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004779</fpage><pub-id pub-id-type="pmid">35738801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2022-004779</pub-id><pub-id pub-id-type="pmcid">PMC9226985</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Lee, P.-C. et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. <italic toggle="yes">J. Immunother. Cancer</italic><bold>10</bold>, e004779 (2022).<pub-id pub-id-type="pmid">35738801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2022-004779</pub-id><pub-id pub-id-type="pmcid">PMC9226985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pederzoli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Stool microbiome signature associated with response to neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer</article-title><source>Eur. Urol.</source><year>2024</year><volume>85</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">38184414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2023.12.014</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Pederzoli, F. et al. Stool microbiome signature associated with response to neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer. <italic toggle="yes">Eur. Urol.</italic><bold>85</bold>, 417&#8211;421 (2024).<pub-id pub-id-type="pmid">38184414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2023.12.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients</article-title><source>Cancer Sci.</source><year>2021</year><volume>112</volume><fpage>3005</fpage><lpage>3017</lpage><pub-id pub-id-type="pmid">34028936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.14979</pub-id><pub-id pub-id-type="pmcid">PMC8353904</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Zhang, C. et al. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients. <italic toggle="yes">Cancer Sci.</italic><bold>112</bold>, 3005&#8211;3017 (2021).<pub-id pub-id-type="pmid">34028936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.14979</pub-id><pub-id pub-id-type="pmcid">PMC8353904</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>LA</given-names></name><name name-style="western"><surname>Al-Massri</surname><given-names>KF</given-names></name></person-group><article-title>Gut microbiota modulation for therapeutic management of various diseases: a new perspective using stem cell therapy</article-title><source>Curr. Mol. Pharm.</source><year>2023</year><volume>16</volume><fpage>43</fpage><lpage>59</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874467215666220222105004</pub-id><pub-id pub-id-type="pmid">35196976</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Ahmed, L. A. &amp; Al-Massri, K. F. Gut microbiota modulation for therapeutic management of various diseases: a new perspective using stem cell therapy. <italic toggle="yes">Curr. Mol. Pharm.</italic><bold>16</bold>, 43&#8211;59 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874467215666220222105004</pub-id><pub-id pub-id-type="pmid">35196976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><mixed-citation publication-type="other">Dougherty, M. W. &amp; Jobin, C. Intestinal bacteria and colorectal cancer: etiology and treatment. <italic toggle="yes">Gut Microbes</italic>. <bold>15</bold>, 2185028 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2023.2185028</pub-id><pub-id pub-id-type="pmcid">PMC10026918</pub-id><pub-id pub-id-type="pmid">36927206</pub-id></mixed-citation></ref><ref id="CR127"><label>127.</label><mixed-citation publication-type="other">Georgiou, K., Marinov, B., Farooqi, A. A. &amp; Gazouli, M. Gut microbiota in lung cancer: where do we stand? <italic toggle="yes">Int. J. Mol. Sci</italic>. <bold>22</bold>, 10429 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms221910429</pub-id><pub-id pub-id-type="pmcid">PMC8508914</pub-id><pub-id pub-id-type="pmid">34638770</pub-id></mixed-citation></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">Temraz, S. et al<italic toggle="yes">.</italic> Hepatocellular carcinoma immunotherapy and the potential influence of gut microbiome. <italic toggle="yes">Int. J. Mol. Sci</italic>. <bold>22</bold>, 7800 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22157800</pub-id><pub-id pub-id-type="pmcid">PMC8346024</pub-id><pub-id pub-id-type="pmid">34360566</pub-id></mixed-citation></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawanabe-Matsuda</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dietary lactobacillus-derived exopolysaccharide enhances immune-checkpoint blockade therapy</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>1336</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">35180303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-0929</pub-id><pub-id pub-id-type="pmcid">PMC9662940</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Kawanabe-Matsuda, H. et al. Dietary lactobacillus-derived exopolysaccharide enhances immune-checkpoint blockade therapy. <italic toggle="yes">Cancer Discov.</italic><bold>12</bold>, 1336&#8211;1355 (2022).<pub-id pub-id-type="pmid">35180303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-0929</pub-id><pub-id pub-id-type="pmcid">PMC9662940</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hejazi</surname><given-names>S</given-names></name><name name-style="western"><surname>Geranmayeh</surname><given-names>MH</given-names></name><name name-style="western"><surname>Shahgolzari</surname><given-names>M</given-names></name><name name-style="western"><surname>Yari Khosroushahi</surname><given-names>A</given-names></name></person-group><article-title>Probiotic immunonutrition impacts on colon cancer immunotherapy and prevention</article-title><source>Eur. J. Cancer Prev.</source><year>2023</year><volume>32</volume><fpage>30</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">36134612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000738</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Nami, Y., Hejazi, S., Geranmayeh, M. H., Shahgolzari, M. &amp; Yari Khosroushahi, A. Probiotic immunonutrition impacts on colon cancer immunotherapy and prevention. <italic toggle="yes">Eur. J. Cancer Prev.</italic><bold>32</bold>, 30&#8211;47 (2023).<pub-id pub-id-type="pmid">36134612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruch</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>602</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">33303685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb5920</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. <italic toggle="yes">Science</italic><bold>371</bold>, 602&#8211;609 (2021).<pub-id pub-id-type="pmid">33303685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb5920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">33542131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abf3363</pub-id><pub-id pub-id-type="pmcid">PMC8097968</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <italic toggle="yes">Science</italic><bold>371</bold>, 595&#8211;602 (2021).<pub-id pub-id-type="pmid">33542131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abf3363</pub-id><pub-id pub-id-type="pmcid">PMC8097968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><etal/></person-group><article-title>From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy</article-title><source>Gut Microbes</source><year>2025</year><volume>17</volume><fpage>2452277</fpage><pub-id pub-id-type="pmid">39826104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2025.2452277</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Lin, A. et al. From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy. <italic toggle="yes">Gut Microbes</italic><bold>17</bold>, 2452277 (2025).<pub-id pub-id-type="pmid">39826104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2025.2452277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors</article-title><source>BMC Med.</source><year>2025</year><volume>23</volume><fpage>341</fpage><pub-id pub-id-type="pmid">40484955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-025-04183-y</pub-id><pub-id pub-id-type="pmcid">PMC12147380</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Lin, A. et al. Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors. <italic toggle="yes">BMC Med.</italic><bold>23</bold>, 341 (2025).<pub-id pub-id-type="pmid">40484955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-025-04183-y</pub-id><pub-id pub-id-type="pmcid">PMC12147380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name></person-group><article-title>Immunotherapy Meets Microbiota</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>1561</fpage><pub-id pub-id-type="pmid">26687344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.12.009</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Tan, J. Immunotherapy Meets Microbiota. <italic toggle="yes">Cell</italic><bold>163</bold>, 1561 (2015).<pub-id pub-id-type="pmid">26687344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.12.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ursell</surname><given-names>LK</given-names></name><name name-style="western"><surname>Parfrey</surname><given-names>LW</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R</given-names></name></person-group><article-title>The impact of the gut microbiota on human health: an integrative view</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>1258</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">22424233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.01.035</pub-id><pub-id pub-id-type="pmcid">PMC5050011</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Clemente, J. C., Ursell, L. K., Parfrey, L. W. &amp; Knight, R. The impact of the gut microbiota on human health: an integrative view. <italic toggle="yes">Cell</italic><bold>148</bold>, 1258&#8211;1270 (2012).<pub-id pub-id-type="pmid">22424233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.01.035</pub-id><pub-id pub-id-type="pmcid">PMC5050011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salgia</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors</article-title><source>Eur. Urol.</source><year>2020</year><volume>78</volume><fpage>498</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">32828600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.07.011</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Salgia, N. J. et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. <italic toggle="yes">Eur. Urol.</italic><bold>78</bold>, 498&#8211;502 (2020).<pub-id pub-id-type="pmid">32828600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.07.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oey</surname><given-names>O</given-names></name><etal/></person-group><article-title>Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: a systematic review</article-title><source>World J. Clin. Oncol.</source><year>2022</year><volume>13</volume><fpage>929</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">36483977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v13.i11.929</pub-id><pub-id pub-id-type="pmcid">PMC9724183</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Oey, O. et al. Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: a systematic review. <italic toggle="yes">World J. Clin. Oncol.</italic><bold>13</bold>, 929&#8211;942 (2022).<pub-id pub-id-type="pmid">36483977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v13.i11.929</pub-id><pub-id pub-id-type="pmcid">PMC9724183</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><mixed-citation publication-type="other">Nie, F. et al. Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy. <italic toggle="yes">Clin. Transl. Oncol</italic>. 10.1007/s12094-024-03615-0. (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12094-024-03615-0</pub-id><pub-id pub-id-type="pmid">39046682</pub-id></mixed-citation></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tinsley</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer</article-title><source>Oncologist</source><year>2020</year><volume>25</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">31292268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2019-0160</pub-id><pub-id pub-id-type="pmcid">PMC6964118</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Tinsley, N. et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. <italic toggle="yes">Oncologist</italic><bold>25</bold>, 55&#8211;63 (2020).<pub-id pub-id-type="pmid">31292268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2019-0160</pub-id><pub-id pub-id-type="pmcid">PMC6964118</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Routy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Gut microbiome influences efficacy of PD-1&#8211;based immunotherapy against epithelial tumors</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">29097494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan3706</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Routy, B. et al. Gut microbiome influences efficacy of PD-1&#8211;based immunotherapy against epithelial tumors. <italic toggle="yes">Science</italic><bold>359</bold>, 91&#8211;97 (2018).<pub-id pub-id-type="pmid">29097494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan3706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glitza</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity</article-title><source>Cancer Discov.</source><year>2024</year><volume>14</volume><fpage>1161</fpage><lpage>1175</lpage><pub-id pub-id-type="pmid">38588588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-24-0066</pub-id><pub-id pub-id-type="pmcid">PMC11215408</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Glitza, I. C. et al. Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. <italic toggle="yes">Cancer Discov.</italic><bold>14</bold>, 1161&#8211;1175 (2024).<pub-id pub-id-type="pmid">38588588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-24-0066</pub-id><pub-id pub-id-type="pmcid">PMC11215408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wind</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma</article-title><source>Melanoma Res.</source><year>2020</year><volume>30</volume><fpage>235</fpage><pub-id pub-id-type="pmid">31990790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CMR.0000000000000656</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Wind, T. T. et al. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. <italic toggle="yes">Melanoma Res.</italic><bold>30</bold>, 235 (2020).<pub-id pub-id-type="pmid">31990790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CMR.0000000000000656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gut microbial structural variation associates with immune checkpoint inhibitor response</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>7421</fpage><pub-id pub-id-type="pmid">37973916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42997-7</pub-id><pub-id pub-id-type="pmcid">PMC10654443</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Liu, R. et al. Gut microbial structural variation associates with immune checkpoint inhibitor response. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 7421 (2023).<pub-id pub-id-type="pmid">37973916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42997-7</pub-id><pub-id pub-id-type="pmcid">PMC10654443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>L</given-names></name><etal/></person-group><article-title>Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>3373</fpage><lpage>3389.e16</lpage><pub-id pub-id-type="pmid">38906102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.05.029</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. <italic toggle="yes">Cell</italic><bold>187</bold>, 3373&#8211;3389.e16 (2024).<pub-id pub-id-type="pmid">38906102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.05.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharti</surname><given-names>R</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>DG</given-names></name></person-group><article-title>Current challenges and best-practice protocols for microbiome analysis</article-title><source>Brief. Bioinform.</source><year>2019</year><volume>22</volume><fpage>178</fpage><lpage>193</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbz155</pub-id><pub-id pub-id-type="pmcid">PMC7820839</pub-id><pub-id pub-id-type="pmid">31848574</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Bharti, R. &amp; Grimm, D. G. Current challenges and best-practice protocols for microbiome analysis. <italic toggle="yes">Brief. Bioinform.</italic><bold>22</bold>, 178&#8211;193 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbz155</pub-id><pub-id pub-id-type="pmcid">PMC7820839</pub-id><pub-id pub-id-type="pmid">31848574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogtmann</surname><given-names>E</given-names></name><etal/></person-group><article-title>Colorectal cancer and the human gut microbiome: Reproducibility with whole-genome shotgun sequencing</article-title><source>PLOS ONE</source><year>2016</year><volume>11</volume><fpage>e0155362</fpage><pub-id pub-id-type="pmid">27171425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0155362</pub-id><pub-id pub-id-type="pmcid">PMC4865240</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Vogtmann, E. et al. Colorectal cancer and the human gut microbiome: Reproducibility with whole-genome shotgun sequencing. <italic toggle="yes">PLOS ONE</italic><bold>11</bold>, e0155362 (2016).<pub-id pub-id-type="pmid">27171425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0155362</pub-id><pub-id pub-id-type="pmcid">PMC4865240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biegert</surname><given-names>G</given-names></name><etal/></person-group><article-title>Diversity and composition of gut microbiome of cervical cancer patients: Do results of 16S rRNA sequencing and whole genome sequencing approaches align?</article-title><source>J. Microbiol Methods</source><year>2021</year><volume>185</volume><fpage>106213</fpage><pub-id pub-id-type="pmid">33785357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mimet.2021.106213</pub-id><pub-id pub-id-type="pmcid">PMC9157377</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Biegert, G. et al. Diversity and composition of gut microbiome of cervical cancer patients: Do results of 16S rRNA sequencing and whole genome sequencing approaches align? <italic toggle="yes">J. Microbiol Methods</italic><bold>185</bold>, 106213 (2021).<pub-id pub-id-type="pmid">33785357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mimet.2021.106213</pub-id><pub-id pub-id-type="pmcid">PMC9157377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><mixed-citation publication-type="other">Analysis of the microbiome: Advantages of whole genome shotgun versus 16S amplicon sequencing. Biochemical and Biophysical Research Communications.<bold>469</bold>, 967&#8211;977 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2015.12.083</pub-id><pub-id pub-id-type="pmcid">PMC4830092</pub-id><pub-id pub-id-type="pmid">26718401</pub-id></mixed-citation></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Risk of Hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2022</year><volume>20</volume><fpage>898</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">34182151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2021.06.019</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Yoo, S. et al. Risk of Hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment. <italic toggle="yes">Clin. Gastroenterol. Hepatol.</italic><bold>20</bold>, 898&#8211;907 (2022).<pub-id pub-id-type="pmid">34182151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2021.06.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition</article-title><source>J. Immunother. Cancer</source><year>2019</year><volume>7</volume><fpage>322</fpage><pub-id pub-id-type="pmid">31753012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0808-5</pub-id><pub-id pub-id-type="pmcid">PMC6873745</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Zhang, X. et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. <italic toggle="yes">J. Immunother. Cancer</italic><bold>7</bold>, 322 (2019).<pub-id pub-id-type="pmid">31753012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0808-5</pub-id><pub-id pub-id-type="pmcid">PMC6873745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy</article-title><source>Front Immunol.</source><year>2024</year><volume>15</volume><fpage>1330644</fpage><pub-id pub-id-type="pmid">38558804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1330644</pub-id><pub-id pub-id-type="pmcid">PMC10979302</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Zeng, Y. et al. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy. <italic toggle="yes">Front Immunol.</italic><bold>15</bold>, 1330644 (2024).<pub-id pub-id-type="pmid">38558804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1330644</pub-id><pub-id pub-id-type="pmcid">PMC10979302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><mixed-citation publication-type="other">Gut Microbiota May Mediate AEs. <italic toggle="yes">Cancer Discov</italic>. <bold>11</bold>, 2118 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-NB2021-0371</pub-id><pub-id pub-id-type="pmid">34373264</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>